WO1994000463A2 - Production of hyaluronic acid by transeformed microorganisms - Google Patents
Production of hyaluronic acid by transeformed microorganisms Download PDFInfo
- Publication number
- WO1994000463A2 WO1994000463A2 PCT/EP1993/001575 EP9301575W WO9400463A2 WO 1994000463 A2 WO1994000463 A2 WO 1994000463A2 EP 9301575 W EP9301575 W EP 9301575W WO 9400463 A2 WO9400463 A2 WO 9400463A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- cell
- acid synthase
- dna
- nucleotide sequence
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 94
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 94
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 94
- 238000004519 manufacturing process Methods 0.000 title abstract description 17
- 244000005700 microbiome Species 0.000 title description 11
- 101710128038 Hyaluronan synthase Proteins 0.000 claims abstract description 183
- 239000012634 fragment Substances 0.000 claims abstract description 70
- 210000004027 cell Anatomy 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 32
- 239000002773 nucleotide Substances 0.000 claims abstract description 31
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 31
- 239000013604 expression vector Substances 0.000 claims abstract description 24
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 16
- 239000001963 growth medium Substances 0.000 claims abstract description 15
- 210000001236 prokaryotic cell Anatomy 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 238000003259 recombinant expression Methods 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 83
- 108020004414 DNA Proteins 0.000 claims description 71
- 102000004169 proteins and genes Human genes 0.000 claims description 54
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 41
- 239000013598 vector Substances 0.000 claims description 32
- 241000588724 Escherichia coli Species 0.000 claims description 20
- 239000012528 membrane Substances 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 238000003786 synthesis reaction Methods 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 241000264435 Streptococcus dysgalactiae subsp. equisimilis Species 0.000 claims description 11
- 239000003599 detergent Substances 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 239000012071 phase Substances 0.000 claims description 8
- HDYANYHVCAPMJV-UHFFFAOYSA-N Uridine diphospho-D-glucuronic acid Natural products O1C(N2C(NC(=O)C=C2)=O)C(O)C(O)C1COP(O)(=O)OP(O)(=O)OC1OC(C(O)=O)C(O)C(O)C1O HDYANYHVCAPMJV-UHFFFAOYSA-N 0.000 claims description 7
- 239000008346 aqueous phase Substances 0.000 claims description 7
- 238000007792 addition Methods 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- WMWKTCPGFOEPBD-YGIWDPDDSA-N azane;(2s,3s,4s,5r,6r)-6-[[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound N.C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O WMWKTCPGFOEPBD-YGIWDPDDSA-N 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 4
- 238000003306 harvesting Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 3
- 230000002779 inactivation Effects 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000001698 pyrogenic effect Effects 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000607720 Serratia Species 0.000 claims description 2
- 241000256251 Spodoptera frugiperda Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- -1 polyethylene Polymers 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000004698 Polyethylene Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract description 15
- 238000011534 incubation Methods 0.000 abstract description 7
- 239000002243 precursor Substances 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 2
- 210000004748 cultured cell Anatomy 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 51
- 239000013612 plasmid Substances 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 19
- 238000010367 cloning Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 239000000523 sample Substances 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 241000194048 Streptococcus equi Species 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 108010003272 Hyaluronate lyase Proteins 0.000 description 4
- 102000001974 Hyaluronidases Human genes 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229960002773 hyaluronidase Drugs 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 108090000637 alpha-Amylases Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108090000145 Bacillolysin Proteins 0.000 description 2
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241001131785 Escherichia coli HB101 Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 102000035092 Neutral proteases Human genes 0.000 description 2
- 108091005507 Neutral proteases Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 108091081548 Palindromic sequence Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 241000120569 Streptococcus equi subsp. zooepidemicus Species 0.000 description 2
- 241000194023 Streptococcus sanguinis Species 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 2
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 239000007621 bhi medium Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- HDYANYHVCAPMJV-USQUEEHTSA-N udp-glucuronic acid Chemical compound O([P@](O)(=O)O[P@](O)(=O)OC[C@H]1[C@@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)[C@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HDYANYHVCAPMJV-USQUEEHTSA-N 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 101150021974 Adh1 gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101100149706 Arabidopsis thaliana SMR10 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 108010066072 DNA modification methylase EcoRI Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101000793655 Oryza sativa subsp. japonica Calreticulin Proteins 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002696 acid base indicator Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940041022 streptomycins Drugs 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
Definitions
- the present invention relates to a DNA fragment encoding the hyaluronic acid synthase (HAS) of Streptococcus equisimilis D181, the nucleotide sequence of this fragment, and the industrial use of this DNA for the production of HAS and hyaluronic acid.
- HAS hyaluronic acid synthase
- Hyaluronic acid is a linear glucosaminoglycan composed of repetitive disaccharide subunits linked togecher by ⁇ (1-4 ) bonds . Each subunit is formed by glucuronic acid bound by a ⁇ (1-3) bond to N-acetylgiucosamine.
- HA has many important functions in humans and animals, for instance in cell lubrication, mobility and adhesion. It therefore plays an important role in cell-to-cell interactions, cell differentiation and tissue repair. Owing to these and its other interesting properties, HA is widely used in the pharmaceutical and health care industries.
- HA can indeed be produced from the A and C groups of streptococci (Lancefield's classification), and it also seems to be a major virulence factor in infections caused by these microorganisms (Wessels et al., Proc. Natl. Acad. Sci. USA, 1991, 88: 8317-8321).
- the HA molecule produced from these bacteria is chemically identical to that obtained from animal tissues, and it is relatively easy to isolate polymers with molecular weights of about two million Daltons (Da) from culture media. It is a generally accepted fact that HA with even higher molecular weights can be used in a wide range of applications thanks to its high viscosity and biocompatibility.
- HAS hyaluronic acid synthase
- the HAS of streptococci consists of a membrane-associated protein of about 52 kDa which may form a complex with one or more proteins (Prehm et al., Biochem. J., 1986, 235: 887-889; Mausolf et al., Biochem. J., 1990, 267: 191-196).
- the activity of HAS in streptococcal membranes is blocked by antibodies directed against the 52 kDa protein (Prehm et al., Biochem. J., 1986, 235: 887-889), indicating that this polypeptide is HAS and constitutes an integral part of the possible complex for HA synthesis.
- the present invention discloses the cloning of an isolated, purified DNA fragment from Streptococcus equisimilis D181 that encodes the HAS protein of about 52 kDa, and the nucleotide sequence of the gene itself, thus allowing the manipulation of the genetics and enzymology of HA synthesis in eukaryotic and prokaryotic cells.
- a clone expressing HAS containing a DNA fragment of about 3.1 kb was identified. This fragment was then subcloned to obtain a ⁇ gtll clone containing an insert of 2.1 kb encoding HAS. The nucleotide sequence of this fragment was determined, and a region encoding a protein of 56 kDa (the molecular weight of which had previously been determined as 52 kDa on the basis or its electrophoretic behavior) was identified. Southern blotting data showed that the HAS gene is conserved in organisms that synthesize HA, and is absent from those that do not produce it.
- an object of the present invention to provide an isolated DNA fragment, comprising a nucleotide sequence encoding hyaluronic acid synthase.
- a further object of the present invention is to provide a prokaryotic or eukaryotic cell transformed with said recombinant expression vector, wherein said cell is capable of producing hyaluronic acid synthase, hyaluronic acid, or both.
- Yet a further object of the present invention is to provide a method of producing hyaluronic acid synthase, comprising: (a) providing a prokaryotic or eukaryotic cell harboring a DNA sequence encoding hyaluronic acid synthase, wherein said DNA sequence is expressible in said cell;
- Another object of the present invention to provide a method of producing hyaluronic acid, comprising:
- a still further object of the present invention is to provide a method of purifying hyaluronic acid synthase, comprising:
- step (b) harvesting said cells of step (a);
- step (f) extracting said hyaluronic acid synthase from said mettibranes by adding a detergent to the membrane suspension of step (e), and then centrifuging to produce a detergent phase containing said hyaluronic acid synthase;
- step (g) adding polyethylene glycol to said detergent phase of step (f), thereby forming an aqueous phase containing said hyaluronic acid synthase; and (h) recovering said hyaluronic acid synthase from said aqueous phase of step (g) .
- a still further object of the present invention is to provide a method of producing hyaluronic acid of varying molecular weight, comprising:
- molecular weight of said hyaluronic acid can be varied by varying the reaction time and/or reaction conditions under which said UDP-GlcA and said UDP-NAcGlc are incubated in the presence of said hyaluronic acid synthase.
- a final object of the present invention is to provide hyaluronic acid produced by the foregoing method, wherein said hyaluronic acid is free of any contaminating proteins, pyrogenic or inflammatory substances, or viruses.
- Fig. 1 shows a comparison between HAS from streptococci and recombinant HAS.
- the HAS was isolated from the protoplastic membranes of Streptococcus equisimilis D181 (A), from E. coli lysates of ⁇ gtll/2LK (B), and ⁇ gtll (C) (negative control).
- the proteins were analyzed by SDS-PAGE and Western blotting, using polyclonal antibodies directed against HAS.
- Fig. 2 shows the strategy for sequencing the HAS gene.
- the DNA of the original ⁇ gtll/2LK clone was digested with the restriction enzyme EcoRI, and the insert of 2.1 kb containing the whole HAS gene was subcloned ( ⁇ gtll/2LK-D, thick arrow). The extent and direction of each sequence is indicated by the fine arrows.
- the region encoding HAS is represented by the rectangle under the 2.1 kb fragment.
- the small rectangles underneath represent the segments verified by amino acid analysis of the HAS purified from streptococci.
- Fig. 3 shows the nucleotide sequence of recombinant HAS and the deduced amino acid sequence.
- the nucleotides are numbered beside the sequence shown from 5' to 3'.
- the deduced amino acid sequence is written under the nucleotide sequence; the residues determined from the peptide sequence are underlined.
- the probable promoter sequence at -35 and -10 marked by a line above the sequence, and the ribosome binding site (SD), are shown in the space above the encoding sequence. Palindromic sequences are shown by broken lines.
- the putative signal peptidase cleavage site is indicated by the arrow.
- Fig. 4 shows the location of inverted sequences in the HAS gene.
- HAS contains two inverted repetitive sequences in its AT rich region before the encoding region and another two which, encompassing the complete coding region, could form a potential loop of 1653 bp.
- Fig. 5 shows the hydrophobic profile of HAS. This graph was generated using Kyte and Doolittle's standard parameters (J. Mol. Biol. 1982, 157: 105-132). The y-axis indicates the hydrophobicity value of the amino acid residues starting from the initiation codon.
- Fig. 6 shows the results of Southern blotting analysis.
- A. Probe PCR product of 3.1 kb derived from ⁇ gtll/2LK; Sample: 1, PCR product; 2, EcoRI digested ⁇ gtll/2LK; 3-6, S. equisimilis genomic DNA, EcoRI - , HindIII-, BamHI-, and EcoRV-digested, respectively; S. equi genomic DNA, same enzymes; 11-14, S. sanguis genomic DNA, same enzymes; 15-18, S. zooepidemicus genomic DNA, same enzymes.
- B. Probe internal fragment XbaI-PstI.
- Sample 1, PCR product; 2, EcoRI digested ⁇ gtll/2LK; 3-6, S. equi genomic DNA, enzymes as in A; 7-10, S. equisimilis genomic DNA, enzymes as in A; 11-14, S. zooepidemicus genomic DNA, enzymes as in A.
- Probe fragment flanking EcoRI.
- Figure 7 shows the cloning strategy used for the construction of pY05.
- the locations of the primers used for PCR are indicated by arrows.
- the coding region for HAS within the ⁇ 2LK fragment is indicated by the thick line.
- the restriction enzymes used in the digestion of the DNA are indicated beside the corresponding arrows.
- Figure 8 shows the cloning strategy used for the construction of pY011.
- the two segments of the HAS coding region are indicated as thick dark lines.
- Figure 9 shows the cloning strategy used for the construction of pY012 and pY014.
- the copy of the HAS coding region derived from FCR amplification (thick dark line) present in pY011 was replaced almost completely with the corresponding fragment from ⁇ 2LK DNA (lighter thick line).
- Figure 10 shows the cloning strategy used for the construction of pY016.
- the ⁇ pLpR promoters and the cI857 represser gene are indicated as thick black and striped arrows, respectively.
- the HAS coding region is indicated as a stippled thickened segment.
- Figure 11 shows the cloning strategy used for the construction of pY019.
- the designation of the different fragments is as in Fig. 10, and the added terminators are indicated as fd-term.
- Figure 12 shows the controlled expression of HAS in E. coli .
- the molecular weight size standards are indicated on the right hand margin.
- Lane la pY09, 30°C; lane lb: pY09, 42°C; lane 2a; pY016, 30°C; lane 2b: pY016, 42°C; lane ⁇ -; ⁇ gtll; lane ⁇ +: ⁇ 2LK.
- Figure 13 shows the growth (OD 600 ) and HA production by recombinant S. equi 68222 strains containing plasmid pY09 and the HAS expression vectors pY016 and pY019.
- Figure 14 shows the analysis of HPLC fractions for HA synthase activity.
- the upper panel shows the protein profile of the various fractions; the molecular weight markers are indicated on the left hand side.
- the lower panel shows the HA synthase activity and the salt concentration of each fraction.
- Figure 15 shows the analysis of HPLC fractions for HA Bynthase activity.
- the upper panel shows the protein profile of the various fractions; the molecular weight markers are indicated on the left hand side.
- the lower panel shows the HA synthase activity, the conductivity, and the OD 280 of each fraction.
- Figure 16 shows the molecular weight distribution of HA in fractions of the reaction mixture of Example 11, using HAS to synthesize hyaluronic acid in vitro.
- the reaction mixture was subjected to gel filtration on Sephacryl S-1000.
- the left peak of the elution profile represents radiolabelled HA; the right peak represents smaller radiolabelled precursors.
- the DNA was treated for 15 minutes at 15°C with 10 U of Klenoe polymerase.
- calf intestine alkaline phosphatase (Boehringer Mannheim, Germany) was used. The reaction was conducted using 1 U of alkaline phosphatase in 20 ⁇ l at 37°C for 30 minutes.
- DNA methylation was carried out using the appropriate methylase according to the manufacturer's instructions.
- T4 DNA iigase (Boehringer Mannheim, Germany) was used at a concentration of 1 U per 0.5 ⁇ g of DNA in a reaction volume of 20 ⁇ l at 14°C for 16 hours.
- Oligonucleotides were synthesized on an Applied Biosystems 380 B DNA synthesizer according to the manufacturer's instructions.
- the Streptococcus equisimilis D181 strain was obtained from the Rockefeller University collection, while the Streptococcus equi 68222 and Streptococcus zooepidemicus 68270 strains were supplied by the "Istituto Sieroterapico Belfanti" in Milan, and the Streptococcus sanguis (Challis) strain was obtained from Dr. Laplace, Jena, Germany. Bacteria were grown in Todd-Hewitt broth or Brain Heart Infusion (BHI) (DIFCO, MI, USA), and plated on culture medium containing 1.5% agar.
- BHI Brain Heart Infusion
- Nucleotide sequences were determined by Sanger's method (Sanger et al., Proc Natl. Acad. Sci. USA. 1977, 74: 5463-5467) using a T7 DNA Polymerase sequencing kit (Pharmacia, Sweden).
- Plasmid DNA was purified with a kit from Quiagen for plasmidic preparations (DIAGEN GmbH, Duesseldorf, Germany).
- Plasmid LNA was sequenced as described by Chen and
- PCR Polymerase Chain Reaction
- nucleic acid sequence and polypeptide disclosed herein, or their biologically functional equivalents can be used in accordance with the present invention.
- biologically functional equivalents denotes fragments, variants, or mutants of nucleic acid sequences or polypeptides exhibiting the same or similar biological activity as the particular nucleic acid sequence and polypeptide shown in Fig. 3.
- Fig. 3 can be altered by substitutions, additions or deletions that provide for biologically functionally equivalent molecules possessing HA synthetic activity similar to that of HAS. Due to the degeneracy of the genetic code, other DNA sequences which encode substantially the same amino acid sequence as depicted in Fig. 3 can be used in the practice of the present invention. These include, but are not limited to, nucleotide sequences comprising all or portions of the HAS gene depicted in Fig. 3 which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Similarly, the HAS protein, or derivatives thereof, of the present invention include, but are not limited to, those containing the amino acid sequence substantially as depicted in Fig.
- amino acid residues within the sequence can be substituted v-ith another amino acid of similar polarity which acts as a functional equivalent, resulting in a silent alteration.
- Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.
- the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanme, tryptophan and methionine.
- the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and giutamine. The positively charged
- (basic) amino acids include arginine, lysine and histidine.
- the negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
- HAS gene of the present invention preferably encodes the protein shown in Fig. 3, also intended to be encompassed by the present invention are fragments or variants of the HAS gene that encode KAS-like proteins possessing the same or similar HA- synthetic biological activity as that of the naturally occurring HAS gene. These fragments or variants can be truncated forms of the protein wherein amino acids from the N-terminal end, C-terminal end, and/or middle of the protein are deleted, or wherein one or more amino acids have been inserted into the natural sequence. Combinations of the foregoing are also encompassed by the present invention.
- DNA fragments derived from streptococcal strains belonging to groups A and C comprising nucleotide sequences homologous to the sequence shown in Fig. 3 that encode the HAS enzyme in these organisms.
- Eukaryotic cDNA sequences encoding HAS are also encompassed by the present invention. It is contemplated that all such fragments, variants, or mutants code for HAS-like proteins that possess substantially the same amino acid sequence as naturally occurring HAS, thereby facilitating the synthesis of HA in a manner similar to that of naturally occurring HAS.
- the variants of HAS should possess more than 801 homology, preferably more than 90% homology, and most preferably more than 95% homology, to natural HAS. To determine this homology, two proteins are aligned so as to obtain a maximum match using gaps and inserts. Homology is determined as the product of the number of matched amino acids divided by the number of total amino acids plus gaps and inserts multiplied by 100.
- the recombinant HAS encoding nucleic acid sequence of the present invention may be engineered so as to modify processing or expression of HAS.
- a Bignal sequence may be inserted upstream of the HAS encoding sequence to permit secretion of HAS, thereby facilitating harvesting or bioavailability.
- a given HAS protein can be mutated in vitro or in vivo to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification.
- Any technique for mutagenesis known in the art can be used, including, but not limited to, in vitro site-directed mutagenesis (Hutchinson et al. (1978) J. Biol. Chem. 253:6551), use of TAB ® linkers (Pharmacia), etc.
- the vectors contemplated for use in the present invention include those into which DNA sequences as discussed herein can be inserted, along with any necessary operational elements. Such vectors can then be subsequently transferred into prokaryotic or eukaryotic host cells and replicated therein.
- Preferred vectors are those whose restriction sites have been well documented and which contain the operational elements preferred or required for transcription of the DNA sequence.
- inventions of the present invention employ vectors which would contain the DNA sequences described herein. It is preferred that all of these vectors have some or all of the following characteristics: (1) possesses a minimal number of host-organism sequences; (2) be stably maintained and propagated in the desired host; (3) be capable of being present in high copy number in the desired host; (4) possess a regulatable promoter positioned so as to promote transcription of the gene of interest; (5) have at least one marker DNA sequence coding for a selectable trait present on a portion of the plasmid separate from that where the DNA sequence will be inserted; and (6) contain a DNA sequence capable of terminating transcription.
- the cloning vectors capable of expressing the DNA sequences of the present invention contain various operational elements. These “operational elements” can include at least one promoter, at least one ShineDalgarno sequence and initiator codon, and at least one termination codon. These “operational elements” may also include one or more of the following: at least one operator, at least one leader sequence for proteins to be exported from intracellular space, at least one gene for a regulator protein, and any other DNA sequences necessary or preferred for appropriate transcription and subsequent translation of the cloned HAS DNA.
- Regulators serve to prevent expression of the DNA sequence in the presence of certain environmental conditions and, in the presence of other environmental conditions, will allow transcription and subsequent expression of the protein coded for by the HAS DNA sequences.
- regulatory segments be inserted into the vector such that expression of the DNA sequence will not occur, or will occur to a greatly reduced extent, in the absence of, for example, isopropylthio-beta-D-galactoside (IPTG).
- IPTG isopropylthio-beta-D-galactoside
- the transformed microorganisms containing the DNA sequence may be grown to a desired density prior to initiation of the expression of HAS. Expression of the desired protein is induced by addition of a substance to the microbial environment capable of causing expression of the DNA sequence after the desired ceil density has been achieved.
- the expression vectors must contain promoters which can be used by the host organism for expression of its own proteins. While the lactose promoter system is commonly used, many other well known viral and microbial promoters have been isolated and characterized, enabling one skilled in the art to use them for expression of HAS and fragments or variants thereof. Transcription Terminators
- the transcription terminators contemplated herein serve to stabilise the vector.
- non-translated sequences include those which stabilize mRNA, as disclosed by Schmeissner et al.
- a ribosome binding site is a sequence which a ribosome recognizes and binds to in the initiation of protein synthesis as set forth in Gold et al., Ann. Rev. Microbiol. 35:557-580 and Marquis et al. (1986) Gene 42:175-183.
- a preferred ribosome binding site is GAGGCGCAAAAA(ATG). Leader Sequences and Translational Couplers
- DNA coding for an appropriate secretory leader (signal) sequence be present at the 5' end of the DNA sequence, as set forth by Watson, M.E. in Nucleic Acids Res. 12:5145-5163, if the protein is to be excreted from the host cytoplasm.
- the DNA for the leader sequence must be in a position that allows the production of a fusion protein in which the leader sequence is immediately adjacent to and covalently joined to HAS, i.e., there must be no transcription or translation signals between the two DNA coding sequences.
- an appropriate leader sequence will allow transport of the completed protein into the periplasmic space, as in the case of some E. coli .
- the appropriate leader sequence will allow transport of the protein through the cell membrane and into the extracellular medium. In this situation, the protein may be purified from extracellular protein.
- An additional DNA sequence can be located immediately preceding the DNA sequence which codes for
- the additional DNA sequence is capable of functioning as a translational coupler, i.e., it is a DNA sequence that encodes an RNA which serves to position ribosomes immediately adjacent to the ribosome binding site of the inhibitor RNA with which it is contiguous.
- the translational coupler may be derived using the DNA sequence TAACGAGGCGCAAAAAATGAAAAAGACAG CTATCGCGATCTTGGAGGATGATTAAATG and methods currently known to those of ordinary skill in the art related to translational couplers.
- the translation terminators contemplated herein serve to stop the translation of mRNA. They may be either natural, as described by Kohli, J., Mol. Gen,
- the cloning vector contain a selectable marker, such as a drug resistance marker or other marker which causes expression of a selectable trait by the host microorganism.
- a selectable marker such as a drug resistance marker or other marker which causes expression of a selectable trait by the host microorganism.
- the gene for ampicillin resistance is included in the vector.
- the gene for tetracycline resistance or the gene for chloramphenicol resistance can be included.
- Such a drug resistance or ether selectable marker facilitates the selection of transformants. Additionally, the presence of such a selectable marker in the cloning vector may be of use in keeping contaminating microorganisms from multiplying in the culture medium. A pure culture of the transformed host microorganisms would be obtained by culturing the microorganisms under conditions which require the induced phenotype for survival.
- the vector can be assembled by methods generally known to those of ordinary skill in the art. Assembly of such vectors is within the ordinary skill in the art, and, as such, is capable of being performed without undue experimentation. Multiple copies of the DNA sequences of the present invention and their accompanying operational elements may be inserted into each vector. In such case, the host organism would produce greater amounts per vector of HAS. The number of multiple copies of the DNA sequence which may be inserted into the vector is limited only by the ability of the resultant vector, due to its size, to be transferred into and replicated and transcribed in an appropriate host cell.
- microorganisms suitable for use in microorganisms other than E. coli are also contemplated for use in the present invention.
- microorganisms include, for example, Streptococci, Bacillus, Pseudomonas,
- Salmonella Salmonella, Serratia, and yeast.
- HAS in vertebrate or invertebrate cells
- vertebrate or invertebrate cells including, for example, Chinese Hamster Ovary cells, VERO cells, HeLa cells, WI38 cells, EHK cells, COS cells, and MDCK cells, as well as insect cells, such as those of Spodoptera frugiperda .
- preferred vectors should include a regulated promoter such as the alpha amylase promoter, the subtilisin promoter, the P-43 promoter, or the spac-126 promoter.
- Useful transcription terminators include rrn and rrn BT.T. Tramscriptional start sites and leader peptides can be chosen from among those from E . amyloliquefaciens neutral protease, B. amyloliquefaciens alpha-amylase, and B. subtil is subtilisin.
- Useful antibiotic markers are Kan r and Cam r . Ribosome binding sites can be obtained from the B , amyloliquefaciens neutral protease and B. amyloliquefaciens alpha-amylase genes.
- a preferred expression system in hosts of the genus Bacillus involves the use of plasmid pUB110 as the cloning vehicle.
- promoters can be selected from Trp, Lac, and Tac.
- Useful transcriptional start sites and leader peptides can be obtained from the phospholipase C and exotoxin A genes.
- Useful antibiotic markers are those for sulfonamides and streptomycins.
- a useful ribosome binding site can be obtained from the Trp promoter of E. coli .
- Particularly preferred vectors would employ the plasmid RSF1010, and derivatives thereof.
- useful promoters include Gal 1 and 10, Adh 1 and 11, and Pho 5.
- Transcription terminators can be chosen from among Cyc, Una, Alpha Factor, and Sac 2.
- Transcriptional start sites and leader peptides can be obtained from the invertase, acid phosphatase, and Alpha factor genes.
- Useful selection markers are Ura 3, Leu 2, His 3, and Tap 1.
- the DNA encoding HAS should have a sequence efficient at binding ribosomes. Such a sequence is described by Kozak in Nucleic Acids Research (1987) 15:8125-6132.
- the HAS-encoding fragment can be inserted into an expression vector containing a transcriptional promoter and a transcriptional enhancer as described by
- the vector should also possess a complete polyadenylation signal as described by Ausubel et al. (1987) in Current Protocols in Molecular Biology, Wiley, so that mRNA transcribed from the vector is properly processed.
- the vector may also contain the replication origin and at least one antibiotic resistance marker from a plasmid such as pBR322, to allow replication and selection in E. coli .
- the expression vector can carry the gene for a selectable marker such as a drug resistance marker or a complementary gene for a deficient cell line, such as a dihydrofolate leduccase
- dhfr gene for transforming a dhfr cell line, as described by Ausubel et al., supra.
- a separate plasmid carrying the selectable marker can be cotransformed along with the expression vector.
- Vectors for mammalian cells can be introduced therein by several techniques, including calcium phosphate:DNA coprecipitation, electroporation, or protoplast fusion. Coprecipitation with calcium phosphate as described by Ausubel et al., supra, is the preferred method.
- Preferred vectors include, for example, a PSVT7 eukaryotic expression plasmid.
- a genomic library was constructed using DNA of Streptococcus equisimilis D181.
- the genomic DNA was partially digested with the restriction enzyme AluI, and the fragments ranging in size from 2 to 4.5 kb were isolated by sucrose gradient centrifugation (J.H. Weis in Current Protocols in Molecular Biology. F.M. Ausubel et al., eds., 1989).
- the isolated fragments were dephosphorylated, methylated with EcoRI methylase, and bound to EcoRI linkers (Wu et al., 1987, in Guide to Molecular Clonin ⁇ Technigues, S. Berger et al., eds., Academic Press, San Diego).
- the linker-containing DNA was digested with EcoRI, separated from the other fragments, ligated to ⁇ gtll DNA, and packaged in infectious virions using the "one-strain-packaging" system SMR10 described by Rosemberg et al. (Gene, 1985, 38: 165-175)
- SMR10 "one-strain-packaging" system SMR10 described by Rosemberg et al. (Gene, 1985, 38: 165-175)
- the packaged DNA was used to transfect E. coli Y1089 (Stratagene).
- the library was screened using polyclonai antibodies directed against HAS, previously affinity purified on the protein itself immobilised on CNBr-Sepharose. Cross-reactive antibodies to E. coli/ ⁇ gtll lysates were removed as described by Sambrook et al.
- HAS HAS was purified from both S. equisimil is D181 and ⁇ gtll/2LK lysatea as described by Prehm and Mausolf (Biochem. J., 235: 887-889, 1986).
- Purified HAS 200 ⁇ g was dissolved in 200 ⁇ i of 6 M urea, diluted with 400 ⁇ l of 20 mM Tris-HCl, pH 7.8, and digested with 5% trypsin or V8 -protease for 24 hours. The mixture was acidified with trifluoroacetic acid and the peptides centrifuged at 10,000 rpm for 3 minutes. The supernatant was applied to a C18 reverse-phase HPLC column (VYDAC 218 TP54).
- Peptides were eluted in 30 minutes with a linear gradient from 0.1% trifluoroacetic acid in water to 0.1% trifluoroacetic acid in 70% acetonitrile with a flow rate of 1 ml/min. Elution was monitored at 220 nm. The fractions were dried and analyzed in a gas phase sequencer. The proteolytic fragments of the synthase, both recombinant ( ⁇ gtll/2LK) and from streptococci, were isolated and analyzed. The same sequence was found in the two preparations, indicating that the recombinant protein was indeed HAS.
- the double-stranded DNA was isolated from ⁇ gtll/2LK-D by Manfiolette's method (Manfiolette et al., Nuc. Acids Res.. 1988, 16: 2873-2884). It was not possible to subclone the whole 2.1 kb fragment in plasrcids such as pGEM-3Z or 7Z (Promega, Madison, WI, USA), pUC-18 (New England BioLabs, Beverly, MA, USA) or pBluescript SR+ (Stratagene, La Jolla, CA, USA), which would have allowed the determination of the nucleotide sequence by a conventional strategy. The insert cloned in E. coli was always shorter than the original.
- the extreme left hand part was sequenced on the ⁇ gtll/2LK-D DNA itself using an fmol DNA sequencing kit (Promega), primer 2 (5'-TTGACACCAGACCAACTGSTAATG-3') labelled with 32 P, and linear amplification. Briefly, 17 ⁇ l of reaction mixture containing 150 ng of ⁇ gtll/2LK-D DNA, 50 mM Tris-HCl, pH 9.0, and 2 mM MgCl, were mixed with a suitable mixture of d/ddNTP, covered with mineral oil, and exposed to 30 cycles of Polymerase Chain Reaction (PCR) (30 seconds at 95°C, 30 seconds at 65°C) after initial denaturation at 95°C for 2 minutes.
- PCR Polymerase Chain Reaction
- ⁇ gtll/2LK-D DNA was sequenced directly according to Snyder's modified protocol (Snyder et al., Meth. Enzymol. , 1987, 154: 107-128). Five ⁇ g of DNA were digested with KpnI and SacI, extracted with phenol, precipitated with ethanol, and resuspended in 20 ⁇ l cf water. The DNA was denatured with 2 ⁇ l of 2 M NaOH, 2 mM EDTA for 10 minutes at 37°C. It was then precipitated with 13 ⁇ l of 1.5 M Na acetate and 2.5 volumes of ice cold ethanol ( ⁇ 20°C), and left in a bath of methanol and dry ice for 10 minutes.
- the DNA was resuspended in 13 ⁇ l of 7.5 mM Tris-KCl, 7.5 mM dithiothreitol, 5 mM MgCl 2 , pH 7.5, 0.7 ng of primers 1 or 2, labelled with 32 P, and incubated at 55°C for 15 minutes. Thereafter, the protocol described for the piasmidic DNA sequence was followed. Finally, restriction fragments of ⁇ gtll/2LK generated by digestion with the enzymes NdeI , Nhel and Rsal were cloned in plasmids and sequenced according to the protocol described. The sequenced fragments are shown in Fig. 2. The amino acid sequence derived from the nucleotide sequence was compared to that of the HAS peptides, and the two proved to be identical.
- Figure 3 shows the complete streptococcal HAS nucleotide sequence and that of the flanking regions with their amino acid sequences.
- the sequences obtained from the isolated peptides are underlined.
- This fragment of DNA can encode a protein of 522 amino acids with an Mr of 56,624.
- the 349-351 codon is probably correct.
- GGAAGG Shine-Delgamo sequence 4 bp before the initiation ATG, very similar to the sequence linked to the ribosomes seen in other Gram positive bacteria.
- a possible promoter for Gram positive bacteria has been identified, shown as an unbroken line above the sequence in Fig. 3, at -35 and -10 (TATACA and TAAAAT), with an ideal space of 16 bp.
- the region immediately before the start is rich in AT (74% vs 57% in the encoding region) in a manner that is characteristic of a promoter region of Gram positive bacteria. Within this AT-rich region there are two inverted sequences (Fig. 4) which could be functional in regulating gene expression.
- Fig. 4 At the end of the complete encoding sequence are two additional inverted sequences (Fig. 4) which could form a potential loop of 1653 bp. Three palindromic sequences are also shown, two inside the encoding region and one after the terminal TAG codon (shown in Fig. 3 as a broken line above the sequence), the function of which is as yet unknown. Streptococcal HAS has been found in protoplastic membranes. It is therefore to be expected that the mature protein is preceded by a signal peptide.
- Figure 5 shows the hydrophobic profile of HAS.
- the first 33 amino acids have the characteristics of a typical bacterial "leader" sequence (Vlasuk et al., J. Biol. Chem.. 1983, 258: 7141-7148): a portion of 12 basic amino acids followed by a hydrophobic core of 14 amino acids terminating with 7 hydrophilic amino acids.
- the DNA was then fixed to the membrane by exposure to UV irradiation for 3 minutes.
- a "DIG Non-radioactive DNA Labeling and Detection Kit” (Boehringer Mannheim, Germany) was used to label the probe and in subsequent stages of the experiment, following the manufacturer's instructions.
- the various purified fragments (about 400 ng each) used as probes were labelled in a non-radioactive fashion by random priming at 37°C for 1 hour.
- the filters onto which the DNA had been transferred were prehybridized in at least 20 ml of hybridization solution (5xSSC, 1% w/v blocking reagent, 0.1% w/v N-laurosylsarccsine sodium salt, 50% formamide) for 2 hours at 42°C, and then hybridized overnight at the same temperature following addition of the labelled, denatured probe to the solution. The filters were then washed and developed. The results are shown in Fig. 5.
- hybridization solution 5xSSC, 1% w/v blocking reagent, 0.1% w/v N-laurosylsarccsine sodium salt, 50% formamide
- HA synthase gene or genes homologous thereto, are conserved in all the streptococcal strains analyzed, thus demonstrating the importance thereof in HA synthesis.
- the HAS genes of streptococcal strains can be isolated by employing the 3.1 kb insert of ⁇ gtll/2LK, or fragments thereof, as probes by techniques well known in the art.
- the repetitive profile observed in D181 suggests that the HAS gene is flanked by a DNA segment peculiar to this organism and of which 5 -10 copies are to be found within the chromosome. This could be an insertion sequence or a transposon.
- the HAS encoding fragment could net be cloned directly from ⁇ gtll/2LK-D due to the presence of unsuitable internal restriction sites. Therefore, attempts were made to introduce suitable restriction sites at both ends of the fragment by PCR amplification of the insert with oligonucleotides containing Ba mHI sites (primer F11: 5'-TTGGATCCGCGACGACTCCTGGAGCCCG-3' and primer R12: 5 '-TTGGATCCCACCAGACCAACTGGTAATG-3' ).
- the fragment was amplified successfully using ⁇ gtll/2LK-D as template and the following amplification protocol: 1 cycle of 2 min 94°C, 2 min 45°C, 5 min 72°C followed by 34 cycles of 1 min 94°C, 2 min 34°C, 5 min 72oC.
- the amplified fragment was digested with the restriction enzyme Xbal, and the right-hand part of the fragment (from the unique internal XbaI site to the end) was cloned, yielding the plasmid pY05.
- the cloning strategy is outlined in Fig. 7, In order to clone the left-hand segment, the primers ST2 and ST3 were used. These primers have the following sequences: ST2 : 5'-CTCTCGAGTTAGGAGGAAGGTCATATGACAGTA-3'; ST3: 5'-CCTAGAGTCTAGATCAGGATTTT-3'.
- 3T2 is located at the beginning of the HAS coding sequence and includes the ribosome binding site and an artificially inti-oduced Xhol site to facilitate subsequent cloning.
- ST3 is located near the internal Xbal site of the cloned insert.
- primers were used to amplify a DNA fragment from ⁇ gtll/2LK using the following protocol: 35 cycles of 1 min 95oC, 1 min 45°C, 1 min 70°C.
- the amplified fragment was subsequently purified and digested with the restriction enzymes XbaI and XhoI.
- the purified fragment was digested with XhoI-XbaI, re-purified, and ligated with the purified Xbal -BamHI fragment from pYO5 and XhoI-BamHI digested pGEM-7Z, and transformed into E. coli HB101 (Promega) to yield plasmid pY011 (Fig. 8).
- Plasmid pY016 does not contain any transcription terminators downstream of the HAS gene. Since it is possible that the presence of terminators may have a positive effect on cloned gene expression by giving rise to more stable mRNA, transcription terminators were added to pY016 in the following manner.
- Plasmids pYC16 and pY09 (the expression vector not containing the HAS encoding gene) were introduced into E. coli ED8739 (Murray et al., Mol. Gen. Genet., 150: 53-61, 1977) by transformation, and transformants were selected on LB agar medium containing 20 ⁇ g/ml of chloramphenicol (Cm). It is well known that the activity of the ⁇ pLpR promoters is blocked by the temperature sensitive repressor cI857 at 30°C, but that the repressor is inactivated at 37°C or above, thus allowing expression of genes under control of the promoters.
- E. coli ED8739 containing pY016 or pY09 was grown in LB containing Cm (20 ⁇ g/ml) at 30°C overnight and subcultured into 2 separate LB cultures which were subsequently incubated at 30 and 42°C for 3h. An aliquot of 1 ml of each culture was transferred to a 1.5 ml Eppsndorf tube, and the cells were pelleted by centrifugation at 15,000xg for 30 sec. Total proteins were extracted by resuspending the pellet in 0.5ml of extraction buffer (2% SDS, 5% (8-mercaptoethanol) and heating tc 95°C for 3 min.
- extraction buffer 2% SDS, 5% (8-mercaptoethanol
- coli ED8739 containing the expression vector pY016 grown at 42oC gives rise to two protein bands of the same size as those observed in the original ⁇ gtll/2LK clone (lane ⁇ +).
- Estimation of the total amount of protein produced indicates that HAS corresponds to about 10% of total cellular protein.
- the presence of the two forms of KA synthase indicates that the signal sequence is also cleaved efficiently from the protein produced by pY016.
- S. equi 68222 containing the plasmids pY09, pY016 or pY019 were compared with respect to the quantity of HA produced.
- Plasmid pY09 was the negative control as it contains only the ⁇ pLpR promoters and the repressor gene, but not the HAS encoding gene. Plasmids pY09, pY016. and pY019 were transformed into S. equi 68222 by electroporation.
- Mucoid colonies of S. equi 68222 containing pY09, pY016 or pY019 were inoculated from BHI agar plates containing 5 ⁇ g/ml Cm into a small volume of BHI plus Cm in Erlenmeyer flasks and grown overnight, on a rotating incubator at 37°C. These overnight cultures were diluted 10-fold in fresh medium containing, in addition, glucose at a final concentration of 2% and the acid-base indicator phenol red at a final concentration of 5 mg/l. The phenol red turns yellow when the culture broth becomes acidic due to the production of lactic acid by the streptococci.
- the results are shown in Fig. 13 and Table 1.
- the strains containing pY016 and pY019 produced higher levels of HA compared to the strain containing pY09, indicating that the presence of multiple copies of the HAS encoding gene favours the more efficient production of HA.
- the quantity of polymer is calculated with respect to the culture OD, it becomes evident that the pY016 and pY019 strains had accumulated approximateiy 1.4-1.5 times more HA than the pY09-containing strain at the end of the cultivation period.
- recombinant prokaryotic cells harboring an expressible DNA sequence encoding HAS can be produced which, when grown under appropriate conditions, produce elevated levels of HAS or hyaluronic acid.
- vectors for the expression of HAS in eukaryotic cells can also be constructed.
- Such recombinant prokaryotic or eukaryotic cells harboring an expressible DNA sequence encoding HAS can be employed as industrial sources of HAS and/or hyaluronic acid. By cuituring these cells under appropriate conditions, it will be possible to recover HAS, hyaluronic acid, or both from the cells themselves, from the culture medium, or from both.
- HAS can be purified according to the following protocol:
- Streptococcus equisimilis D181, or any alternative cells capable of producing HA such as related Lancefield's group A or C streptococcal species or recombinant organisms expressing HAS, is grown in the desired volume of Todd-Hewitt broth or any ether suitable nutrient medium at a temperature retween 50 and 40°C, but preferably at 37°C, to a final OD 600 greater than 0.1, and preferably about 0.5. Approximately 1 h before cell harvesting, 6,000 units per liter of hyaluronidase can be added to degrade any KA produced.
- the bacteria are harvested by centrifugation, washed at least two times with a suitable buffer such as cold phosphate buffered saline (PBS), and resuspended in a final volume of between 100 and 1,000 ml, but preferably in 200 ml, of PBS containing approximately 1 mM dithiothreitol.
- a suitable buffer such as cold phosphate buffered saline (PBS)
- PBS cold phosphate buffered saline
- This suspension is subjected to procedures designed to cause cell disruption, such as sonication at 0°C, under conditions sufficient to ensure complete cell disruption while minimizing enzyme inactivation.
- sonication conditions can be used, but those preferred are 15 min. at 120 watts. Subsequent operations are carried out at 4°C.
- Bacterial debris is removed by centrifugation, and the supernatant is subjected to ultracentrifugation under conditions capable of sedimenting the bacterial membranes, preferably at 40,000 rpm for 30 min.
- the sediment which contains the streptococcal membranes, is suspended in a small volume of 50 mM Trismalonate buffer, or any other suitable buffer, containing approximately 1 mM dithiothreitol, by sonication under mild conditions, for example 30 sec. at 20 watts.
- the protein concentration is determined, and the suspension is diluted in the same buffer to a final protein concentration of between 1 and 10 mg/mi, but preferably at 3 mg/ml.
- a 10% solution of a mild detergent such as digitonin is added to the sample to give a final concentration of between 0.5 and 2%, but preferably 1%.
- the suspension is stirred in order to ensure thorough mixing for approximately 1 hour, and subjected to ultracentrifugaticn in order to separate membrane fragments at 40,000xg for 30 min. or other similar conditions.
- the following compounds are added: 1 ml of a 50% solution of PEG 6000, between 0.025 and 0.1 ml, but preferably 0.05 ml, of a 1 M solution of MgCl 2 , between 0.5 and 5 mg, but preferably 2 mg each, of UDP-N-acetylglucosamine and UDP-glucuronic acid.
- the mixture is incubated under conditions suitable for the synthesis of HA, for example at 37°C for 30 min., and is subsequently rapidly cooled to 0°C in an ice/salt bath. An additional aliquot of 1 ml of 50% PEG 6000 is added, and the solution is vortexed.
- the solution becomes turbid, indicating that phase separation has taken place.
- the suspension is again subjected to ultracentrifugation, for example at 40,000 rpm, for 30 min. 8.
- a large number of approaches can be used, including HPLC chromatography.
- the supernatant is subjected to HPLC on an ion-exchange column such as a Waters DSAE-protein Pak 5PW, 7.5 mm ⁇ 7.5 mm, which has been equilibrated with a suitable buffer such as 50 mM Tris-maionate buffer, pH 7.0, containing a detergent such as digitonin at a final concentration of about 0.5%.
- the sample is pumped onto the column at the desired flow rate, preferably at the rate of 1 ml/min.
- the column is washed with the starting buffer, and proteins can be eluted by progressively increasing the salt concentration of the buffer, for example from 0 to 0.5 M, in 30 min. with a constant flow rate of iml/min. Fractions of the desired volume can be collected; a volume of 1 ml is suitable.
- each fraction contains active HAS.
- determinations include: absorbance at 280 nm, conductivity, and HAS activity as determined using radiolabelled precursor as described previously by Prehm (Biochem. J.. 1983, 211:181-189).
- the protein pattern of each fraction can be analysed by polyacrylamide gel electrophoresis following precipitation of the proteins from a fixed volume of each fraction, for example 200 ⁇ l, by standard techniques such as that described by Wessel and Flugge (Anal. Biochem., 1984, 138:141-143).
- Hyaluronic acid of varying molecular weight for different applications can be synthesized in vitro using purified HAS.
- purified HAS is diluted in 50 mM Tris-malonate buffer, or any other suitable buffer, to a final protein concentration of between 0.01 and 1.0 mg/ml, but preferably at 0.1 mg/ml.
- dithiothreitol to a final concentration of approximately 1 mM
- MgCl 2 to final concentration of approximately 10 mM
- UDP-GlcA and UDP-NAcGlc both in concentrations to between 0.1 and 5 mM, but preferably to 1 mM, are added.
- the mixture is incubated under conditions suitable for the synthesis of HA, for example at 37°C for 4 hours, and subjected to gel filtration on a Sephacryl S-1000 (83 cm ⁇ 1 cm) column or any other suitable column.
- the HA is eluted with PBS or any other suitable buffer.
- the results are shown in Fig. 16.
- the molecular weight cf the HA synthesized in vitro for 4 hours at 37°C using purified HAS is about 350,000 Da.
- the molecular weight of HA synthesized in vitro employing HAS can be varied by varying the incubation period and/or reaction conditions, with the molecular weight varying with varying incubation time ana reaction conditions in the presence of HAS.
- Those reaction conditions which can be varied to influence the molecular weight of the final HA product include, but are not limited to, pH, temperature, etc.
- the pH can be varied between 4.2 and 8.9; a decrease in pH results in a decrease in molecular weight of HA. With respect to the effect of temperature, this may be varied between 10 to 40°C; a decrease in temperature results in a decrease in molecular weight of the HA produced.
- HA produced in this manner possesses the highly desirable property for pharmaceutical and other related applications that it is extremely pure as compared to HA purified from conventional sources, and does not contain any contaminating proteins, pyrogenic or inflammatory substances, or viruses.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
An isolated DNA fragment comprising a nucleotide sequence encoding hyaluronic acid synthase is provided. Also provided are recombinant expression vectors comprising this sequence, capable of expressing hyaluronic acid synthase in prokaryotic and eukaryotic cells, as well as host cells harboring such expression vectors. Such cells are capable of producing hyaluronic acid synthase, hyaluronic acid, or both, which can be recovered from these cells, the culture medium, or both. Also provided are a method of producing hyaluronic acid synthase, methods of producing hyaluronic acid both in vivo and in vitro, and hyaluronic acid produced by these methods. In the case of in vitro production, the molecular weight of hyaluronic acid can be varied by varying the time of incubation of hyaluronic acid precursors in the presence of hyaluronic acid synthase and/or the reaction conditions. Lastly, a method of purifying hyaluronic acid synthase from cultured cells is also provided.
Description
DNA ENCODING HYALURONIC ACID SYNTHASE (HAS) ,
EXPRESSION VECTORS CONTAINING THIS GENE, AND
PRODUCTION OF HYALURONIC ACID BY TRANSFORMED
MICROORGANISMS AND IN VITRO
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention relates to a DNA fragment encoding the hyaluronic acid synthase (HAS) of Streptococcus equisimilis D181, the nucleotide sequence of this fragment, and the industrial use of this DNA for the production of HAS and hyaluronic acid.
Description of Related Art
Hyaluronic acid (HA) is a linear glucosaminoglycan composed of repetitive disaccharide subunits linked togecher by β (1-4 ) bonds . Each subunit is formed by glucuronic acid bound by a β(1-3) bond to N-acetylgiucosamine. A ubiquitous component of the extracellular matrix, HA has many important functions in humans and animals, for instance in cell lubrication, mobility and adhesion. It therefore plays an important role in cell-to-cell interactions, cell differentiation
and tissue repair. Owing to these and its other interesting properties, HA is widely used in the pharmaceutical and health care industries.
Until recently, this polymer was commonly obtained by purification from animal sources such as rooster combs. This source of raw material presents certain disadvantages such as the fact that it offers limited yields and because purification of the high molecular weight polymer is hampered by HA's tendency to form complexes with other molecules, including proteins. To overcome these problems, there have been efforts in recent years to investigate streptococci as an alternative source of HA.
HA can indeed be produced from the A and C groups of streptococci (Lancefield's classification), and it also seems to be a major virulence factor in infections caused by these microorganisms (Wessels et al., Proc. Natl. Acad. Sci. USA, 1991, 88: 8317-8321). The HA molecule produced from these bacteria is chemically identical to that obtained from animal tissues, and it is relatively easy to isolate polymers with molecular weights of about two million Daltons (Da) from culture media. It is a generally accepted fact that HA with even higher molecular weights can be used in a wide range of applications thanks to its high viscosity and biocompatibility.
SUMMARY OF THE INVENTION
The production of high purity HA of varying molecular weights for particular applications can be achieved by obtaining a more detailed understanding of the mechanism of synthesis of HA at the molecular level, and using this information to generate new HA polymers, thus broadening the scope of its existing applications and creating new ones.
Recently, much effort has been expended in studying the activity of the enzyme responsible for HA synthesis, hyaluronic acid synthase (HAS). HAS has been found to be associated with the plasma membrane in both mammalian and bacterial cells (Markovitz et al., J. Biol. Chem., 1962, 237: 273-279; P. Prehm, Biochem. J., 1984, 220; 597-600) where it acts as a catalyst for polymerization of the precursors UDP-glucuronic acid and UDP-N-acetylglucosamine to form the extracellular linear molecule of HA. Various attempts have been made to study HAS components in more detail by purifying the enzyme. Purification from mammalian cells has proved unsuccessful, thus focusing attention on bacterial systems. By using different techniques--isolation of the protein linked with the newly-formed HA, purification of an enzymatically active synthase, isolation of mutant strains of streptococci that do not produce HA- -it has been shown that the HAS of streptococci consists of a membrane-associated protein of about 52 kDa which may form a complex with one or more proteins (Prehm et al., Biochem. J., 1986, 235: 887-889; Mausolf et al., Biochem. J., 1990, 267: 191-196). The activity of HAS in streptococcal membranes is blocked by antibodies directed against the 52 kDa protein (Prehm et al., Biochem. J., 1986, 235: 887-889), indicating that this polypeptide is HAS and constitutes an integral part of the possible complex for HA synthesis.
The identification of the protein component(s) involved in HA synthesis and the cloning of the corresponding gene(s) offers considerable potential. The cloning of the relevant gene(s) under the control of the natural promoter or an alternative strongly active promoter would allow the construction of recombinant bacterial strains which could be used either as more efficient producers of HA or as sources of purified HAS.
The ability to isolate sufficient quantities of highly purified active HAS would permit the development of an efficient in vitro synthetic method for HA production. HA produced by such a system would offer considerable advantages over the presently available products extracted from animal or bacterial sources. For example, using an immobilized enzyme system, production of HA of practically 100% purity would be possible. By using varying reaction times and/or conditions, the molecular weight of the resulting polymer could be controlled, thus allowing the synthesis of HA of particular molecular weights for specific applications. The possibility of using synchronized reaction conditions would permit the polydispersity of the molecular weight to be controlled, also thus resulting in a much more homogeneous product. Japanese Patent Application LaidOpen JP 90231093 A2 discloses an in vitro system for the preparation of HA. However, rather than employing purified HAS, streptococcal membranes are employed. The present invention discloses the cloning of an isolated, purified DNA fragment from Streptococcus equisimilis D181 that encodes the HAS protein of about 52 kDa, and the nucleotide sequence of the gene itself, thus allowing the manipulation of the genetics and enzymology of HA synthesis in eukaryotic and prokaryotic cells.
A procedure has been disclosed which allegedly allows the isolation of a DNA fragment from Streptococcus equisimilis D181 encoding hyaluronic acid synthase (PCT publication No. WO 91/03559). The scientific data contained therein are insufficient to prove that the DNA fragment isolated effectively encodes this enzyme, and do not permit those of skill in the art to repeat the manipulations to obtain the putative HA synthase-encoding clone.
Using recombinant DNA techniques, the present inventors constructed a genomic bank of Streptococcus equisimilis D181 DNA in λgtll. The clones encoding HAS were isolated using antibodies directed against the HAS protein of about 52 kDa. A clone expressing HAS containing a DNA fragment of about 3.1 kb was identified. This fragment was then subcloned to obtain a λgtll clone containing an insert of 2.1 kb encoding HAS. The nucleotide sequence of this fragment was determined, and a region encoding a protein of 56 kDa (the molecular weight of which had previously been determined as 52 kDa on the basis or its electrophoretic behavior) was identified. Southern blotting data showed that the HAS gene is conserved in organisms that synthesize HA, and is absent from those that do not produce it.
Accordingly, it is an object of the present invention to provide an isolated DNA fragment, comprising a nucleotide sequence encoding hyaluronic acid synthase.
It is another object of the present invention to provide a recombinant expression vector, comprising a nucleotide sequence encoding hyaluronic acid synthase, wherein said vector is capable of expressing said hyaluronic acid synthase in a transformed prokaryotic or eukaryotic cell.
A further object of the present invention is to provide a prokaryotic or eukaryotic cell transformed with said recombinant expression vector, wherein said cell is capable of producing hyaluronic acid synthase, hyaluronic acid, or both.
Yet a further object of the present invention is to provide a method of producing hyaluronic acid synthase, comprising:
(a) providing a prokaryotic or eukaryotic cell harboring a DNA sequence encoding hyaluronic acid synthase, wherein said DNA sequence is expressible in said cell;
(b) culturing said cell in a culture medium; and (c) recovering said hyaluronic acid synthase from said cell or from said culture medium.
Another object of the present invention to provide a method of producing hyaluronic acid, comprising:
(a) providing a recombinant prokaryotic or eukaryotic cell harboring a DNA sequence encoding hyaluronic acid synthase, wherein said DNA sequence is expressible in said cell;
(b) culturing said cell in a culture medium; and (c) recovering said hyaluronic acid from said cell or from said culture medium.
A still further object of the present invention is to provide a method of purifying hyaluronic acid synthase, comprising:
(a) culturing cells expressing a gene encoding hyaluronic acid synthase;
(b) harvesting said cells of step (a);
(c) disrupting said cells under conditions that minimize the inactivation of hyaluronic acid synthase;
(d) isolating membranes of said cells;
(e) suspending said membranes in a buffer;
(f) extracting said hyaluronic acid synthase from said mettibranes by adding a detergent to the membrane suspension of step (e), and then centrifuging to produce a detergent phase containing said hyaluronic acid synthase;
(g) adding polyethylene glycol to said detergent phase of step (f), thereby forming an aqueous phase containing said hyaluronic acid synthase; and
(h) recovering said hyaluronic acid synthase from said aqueous phase of step (g) .
A still further object of the present invention is to provide a method of producing hyaluronic acid of varying molecular weight, comprising:
(a) incubating UDP-GlcA and UDP-NAcGlc with hyaluronic acid synthase under conditions suitable for the synthesis of hyaluronic acid; and
(b) recovering hyaluronic acid,
wherein the molecular weight of said hyaluronic acid can be varied by varying the reaction time and/or reaction conditions under which said UDP-GlcA and said UDP-NAcGlc are incubated in the presence of said hyaluronic acid synthase.
A final object of the present invention is to provide hyaluronic acid produced by the foregoing method, wherein said hyaluronic acid is free of any contaminating proteins, pyrogenic or inflammatory substances, or viruses.
Further scope of the applicability of the present invention will become apparent from the detailed description and drawings provided below. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
The above and other objects, features, and advantages of the present invention will be better understood from the following detailed descriptions taken in conjunction with the accompanying drawings, all
of which are given by way of illustration only, and are not limitative of the present invention, in which:
Fig. 1 shows a comparison between HAS from streptococci and recombinant HAS. The HAS was isolated from the protoplastic membranes of Streptococcus equisimilis D181 (A), from E. coli lysates of λgtll/2LK (B), and λgtll (C) (negative control). The proteins were analyzed by SDS-PAGE and Western blotting, using polyclonal antibodies directed against HAS.
Fig. 2 shows the strategy for sequencing the HAS gene. The DNA of the original λgtll/2LK clone was digested with the restriction enzyme EcoRI, and the insert of 2.1 kb containing the whole HAS gene was subcloned (λgtll/2LK-D, thick arrow). The extent and direction of each sequence is indicated by the fine arrows. The region encoding HAS is represented by the rectangle under the 2.1 kb fragment. The small rectangles underneath represent the segments verified by amino acid analysis of the HAS purified from streptococci.
Fig. 3 shows the nucleotide sequence of recombinant HAS and the deduced amino acid sequence. The nucleotides are numbered beside the sequence shown from 5' to 3'. The deduced amino acid sequence is written under the nucleotide sequence; the residues determined from the peptide sequence are underlined. The probable promoter sequence at -35 and -10, marked by a line above the sequence, and the ribosome binding site (SD), are shown in the space above the encoding sequence. Palindromic sequences are shown by broken lines. The putative signal peptidase cleavage site is indicated by the arrow.
Fig. 4 shows the location of inverted sequences in the HAS gene. HAS contains two inverted repetitive sequences in its AT rich region before the encoding region and another two which, encompassing the complete coding region, could form a potential loop of 1653 bp.
Fig. 5 shows the hydrophobic profile of HAS. This graph was generated using Kyte and Doolittle's standard parameters (J. Mol. Biol. 1982, 157: 105-132). The y-axis indicates the hydrophobicity value of the amino acid residues starting from the initiation codon.
Fig. 6 shows the results of Southern blotting analysis.
A. Probe: PCR product of 3.1 kb derived from λgtll/2LK; Sample: 1, PCR product; 2, EcoRI digested λgtll/2LK; 3-6, S. equisimilis genomic DNA, EcoRI - , HindIII-, BamHI-, and EcoRV-digested, respectively; S. equi genomic DNA, same enzymes; 11-14, S. sanguis genomic DNA, same enzymes; 15-18, S. zooepidemicus genomic DNA, same enzymes.
B. Probe: internal fragment XbaI-PstI. Sample: 1, PCR product; 2, EcoRI digested λgtll/2LK; 3-6, S. equi genomic DNA, enzymes as in A; 7-10, S. equisimilis genomic DNA, enzymes as in A; 11-14, S. zooepidemicus genomic DNA, enzymes as in A.
C. Probe: fragment flanking EcoRI. Sample as in B. Figure 7 shows the cloning strategy used for the construction of pY05. The locations of the primers used for PCR are indicated by arrows. The coding region for HAS within the λ2LK fragment is indicated by the thick line. The restriction enzymes used in the digestion of the DNA are indicated beside the corresponding arrows.
Figure 8 shows the cloning strategy used for the construction of pY011. The two segments of the HAS coding region are indicated as thick dark lines.
Figure 9 shows the cloning strategy used for the construction of pY012 and pY014. The copy of the HAS coding region derived from FCR amplification (thick dark line) present in pY011 was replaced almost completely with the corresponding fragment from λ2LK DNA (lighter thick line).
Figure 10 shows the cloning strategy used for the construction of pY016. The λpLpR promoters and the cI857 represser gene are indicated as thick black and striped arrows, respectively. The HAS coding region is indicated as a stippled thickened segment.
Figure 11 shows the cloning strategy used for the construction of pY019. The designation of the different fragments is as in Fig. 10, and the added terminators are indicated as fd-term.
Figure 12 shows the controlled expression of HAS in E. coli . The molecular weight size standards are indicated on the right hand margin. Lane la: pY09, 30°C; lane lb: pY09, 42°C; lane 2a; pY016, 30°C; lane 2b: pY016, 42°C; lane λ-; λgtll; lane λ+: λ2LK.
Figure 13 shows the growth (OD600) and HA production by recombinant S. equi 68222 strains containing plasmid pY09 and the HAS expression vectors pY016 and pY019.
Figure 14 shows the analysis of HPLC fractions for HA synthase activity. The upper panel shows the protein profile of the various fractions; the molecular weight markers are indicated on the left hand side. The lower panel shows the HA synthase activity and the salt concentration of each fraction.
Figure 15 shows the analysis of HPLC fractions for HA Bynthase activity. The upper panel shows the protein profile of the various fractions; the molecular weight markers are indicated on the left hand side. The lower panel shows the HA synthase activity, the conductivity, and the OD280 of each fraction.
Figure 16 shows the molecular weight distribution of HA in fractions of the reaction mixture of Example 11, using HAS to synthesize hyaluronic acid in vitro. The reaction mixture was subjected to gel filtration on Sephacryl S-1000. The left peak of the elution profile represents radiolabelled HA; the right peak represents smaller radiolabelled precursors.
DETAILED DESCRIPTION OF THE INVENTION
The following detailed description of the invention is provided to aid those skilled in the art in practicing the same. Even so, the following detailed description should not be construed to unduly limit the present invention, as modifications and variations in the embodiments herein discussed may be made by those of ordinary skill in the art without departing from the spirit or scope of the present inventive discovery.
The contents of each of the references cited in the present disclosure are herein incorporated by reference in their entirety.
General Recombinant DNA Techniques
The conventional molecular techniques employed were those described by Sambrook (Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
Cleavage of DNA with restriction enzymes was performed according to the manufacturers' instructions. In general, 1 μg of plasmid DNA was cut with 1 U of enzyme in 20 μl of solution; temperature and incubation times depended on the enzyme used, but were usually 1 hour at 37°C. After incubation, DNA fragments were purified in LMP agarose gels (BRL, U.S.A.) in 40 mM Tris-HCl, 20 mM sodium acetate, 1 mM EDTA, and then
eluted from the agarose with a Geneclean(TM) kit (BIO101 Inc., La Jolla, CA, U.S.A.).
For the filling in reaction at the 5' end, the DNA was treated for 15 minutes at 15°C with 10 U of Klenoe polymerase. To dephosphorylate the DNA cut with the restriction enzymes, calf intestine alkaline phosphatase (Boehringer Mannheim, Germany) was used. The reaction was conducted using 1 U of alkaline phosphatase in 20 μl at 37°C for 30 minutes. When necessary, DNA methylation was carried out using the appropriate methylase according to the manufacturer's instructions. For ligation reactions, T4 DNA iigase (Boehringer Mannheim, Germany) was used at a concentration of 1 U per 0.5 μg of DNA in a reaction volume of 20 μl at 14°C for 16 hours.
Oligonucleotides were synthesized on an Applied Biosystems 380 B DNA synthesizer according to the manufacturer's instructions.
The Streptococcus equisimilis D181 strain was obtained from the Rockefeller University collection, while the Streptococcus equi 68222 and Streptococcus zooepidemicus 68270 strains were supplied by the "Istituto Sieroterapico Belfanti" in Milan, and the Streptococcus sanguis (Challis) strain was obtained from Dr. Laplace, Jena, Germany. Bacteria were grown in Todd-Hewitt broth or Brain Heart Infusion (BHI) (DIFCO, MI, USA), and plated on culture medium containing 1.5% agar.
Purification of HAS from the protoplastic membranes of the streptococci and production of the antibodies used to isolate the HAS-producing clones has been describedby Prehm and Mausolf (Biochem. J., 1986, 235: 887-889).
Genomic DNA was isolated as fellows. A colony of streptococci was inoculated into 5 ml of Todd-Hewitt
broth containing 40 mM D,L-threonine and 30 mM glucose, and left to grow while being shaken overnight at 37°C. The culture was then diluted in 100 ml of Todd-Hewitt broth containing threonine alone. To this were then added cysteine (final concentration: 6 mM) at OD600 = 0.03 and hyaluronidase (3 units/ml) at OD600 = 0.1. Growth was stopped at OD600 = 0.5, and the bacteria harvested by centrifugation at 5,000 rpm, washed twice with 10 mM Tris-HCl, 1 mM EDTA, pH 7.5, at 0°C, resuspended in 8.75 ml of said buffer, and incubated with lysozyme (5mg/ml) and hyaluronidase (1.5 units/ml) for one hour at 37°C. Proteinase K and Pronase B were then added (250 μg/ml each) and the solution was left for another 30 minutes at the same temperature. SDS was then added to a final concentration of 0.5%, and incubation was continued at 37°C until the solution became clear, indicating bacterial lysis. NaCl and CTAB (Sigma) were then added to a final concentration of 0.7 M and 1.13%, respectively. The solution thus obtained was extracted once with an equal volume of chloroform/isoamyl alcohol (24:1, v/v). The phases were separated by centrifugation at 6,000 rpm for 10 minutes. The aqueous phases were harvested and the DNA was precipitated with 0.6 volumes of isopropanol.
Nucleotide sequences were determined by Sanger's method (Sanger et al., Proc Natl. Acad. Sci. USA. 1977, 74: 5463-5467) using a T7 DNA Polymerase sequencing kit (Pharmacia, Sweden).
Plasmid DNA was purified with a kit from Quiagen for plasmidic preparations (DIAGEN GmbH, Duesseldorf, Germany).
Plasmid LNA was sequenced as described by Chen and
Seeburg (DNA, 1985, 4: 165-170). DNA amplified by the
Polymerase Chain Reaction (PCR) (Saiki et al., Science, 1988, 239: 487-491) was sequenced as described by Both
et al. (Anal. Biochem., 1991, 199: 216-218) using primers from the inner nucleotide sequence of the HAS gene. The DNA of λgtll/2LK-D was sequenced with an fmol.TM) DNA sequencing kit (Promega, Madison, WT, USA) using a linear amplification protocol.
HAS Genes and Proteins
The nucleic acid sequence and polypeptide disclosed herein, or their biologically functional equivalents, can be used in accordance with the present invention. The term "biologically functional equivalents," as used herein, denotes fragments, variants, or mutants of nucleic acid sequences or polypeptides exhibiting the same or similar biological activity as the particular nucleic acid sequence and polypeptide shown in Fig. 3.
For example, the nucleic acid sequence depicted in
Fig. 3 can be altered by substitutions, additions or deletions that provide for biologically functionally equivalent molecules possessing HA synthetic activity similar to that of HAS. Due to the degeneracy of the genetic code, other DNA sequences which encode substantially the same amino acid sequence as depicted in Fig. 3 can be used in the practice of the present invention. These include, but are not limited to, nucleotide sequences comprising all or portions of the HAS gene depicted in Fig. 3 which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Similarly, the HAS protein, or derivatives thereof, of the present invention include, but are not limited to, those containing the amino acid sequence substantially as depicted in Fig. 3, including altered sequences in which physiologically functionallyequivalent amino acid residues are substituted for residues within the sequence, also resulting in a silent
change. For example, one or more amino acid residues within the sequence can be substituted v-ith another amino acid of similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanme, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and giutamine. The positively charged
(basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
While the HAS gene of the present invention preferably encodes the protein shown in Fig. 3, also intended to be encompassed by the present invention are fragments or variants of the HAS gene that encode KAS-like proteins possessing the same or similar HA- synthetic biological activity as that of the naturally occurring HAS gene. These fragments or variants can be truncated forms of the protein wherein amino acids from the N-terminal end, C-terminal end, and/or middle of the protein are deleted, or wherein one or more amino acids have been inserted into the natural sequence. Combinations of the foregoing are also encompassed by the present invention.
Also encompassed by the present invention are DNA fragments derived from streptococcal strains belonging to groups A and C (Lancefield's classification), comprising nucleotide sequences homologous to the sequence shown in Fig. 3 that encode the HAS enzyme in these organisms. Eukaryotic cDNA sequences encoding HAS are also encompassed by the present invention.
It is contemplated that all such fragments, variants, or mutants code for HAS-like proteins that possess substantially the same amino acid sequence as naturally occurring HAS, thereby facilitating the synthesis of HA in a manner similar to that of naturally occurring HAS.
The variants of HAS should possess more than 801 homology, preferably more than 90% homology, and most preferably more than 95% homology, to natural HAS. To determine this homology, two proteins are aligned so as to obtain a maximum match using gaps and inserts. Homology is determined as the product of the number of matched amino acids divided by the number of total amino acids plus gaps and inserts multiplied by 100.
In addition, the recombinant HAS encoding nucleic acid sequence of the present invention may be engineered so as to modify processing or expression of HAS. For example, and not by way of limitation, a Bignal sequence may be inserted upstream of the HAS encoding sequence to permit secretion of HAS, thereby facilitating harvesting or bioavailability.
Additionally, a given HAS protein can be mutated in vitro or in vivo to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification. Any technique for mutagenesis known in the art can be used, including, but not limited to, in vitro site-directed mutagenesis (Hutchinson et al. (1978) J. Biol. Chem. 253:6551), use of TAB® linkers (Pharmacia), etc.
Expression Vectors for HAS
The vectors contemplated for use in the present invention include those into which DNA sequences as discussed herein can be inserted, along with any necessary operational elements. Such vectors can then be subsequently transferred into prokaryotic or eukaryotic host cells and replicated therein. Preferred vectors are those whose restriction sites have been well documented and which contain the operational elements preferred or required for transcription of the DNA sequence.
Certain embodiments of the present invention employ vectors which would contain the DNA sequences described herein. It is preferred that all of these vectors have some or all of the following characteristics: (1) possesses a minimal number of host-organism sequences; (2) be stably maintained and propagated in the desired host; (3) be capable of being present in high copy number in the desired host; (4) possess a regulatable promoter positioned so as to promote transcription of the gene of interest; (5) have at least one marker DNA sequence coding for a selectable trait present on a portion of the plasmid separate from that where the DNA sequence will be inserted; and (6) contain a DNA sequence capable of terminating transcription.
The cloning vectors capable of expressing the DNA sequences of the present invention contain various operational elements. These "operational elements" can include at least one promoter, at least one ShineDalgarno sequence and initiator codon, and at least one termination codon. These "operational elements" may also include one or more of the following: at least one operator, at least one leader sequence for proteins to be exported from intracellular space, at least one gene for a regulator protein, and any other DNA sequences
necessary or preferred for appropriate transcription and subsequent translation of the cloned HAS DNA.
Certain of these operational elements may be present in the preferred vectors of the present invention. It is contemplated that any additional operational elements which may be required may be identified and added to these vectors using methods known to those of ordinary skill in the art, such as those described by Sambrook et al., supra.
Regulators
Regulators serve to prevent expression of the DNA sequence in the presence of certain environmental conditions and, in the presence of other environmental conditions, will allow transcription and subsequent expression of the protein coded for by the HAS DNA sequences. In particular, it is preferred that regulatory segments be inserted into the vector such that expression of the DNA sequence will not occur, or will occur to a greatly reduced extent, in the absence of, for example, isopropylthio-beta-D-galactoside (IPTG). In this situation, the transformed microorganisms containing the DNA sequence may be grown to a desired density prior to initiation of the expression of HAS. Expression of the desired protein is induced by addition of a substance to the microbial environment capable of causing expression of the DNA sequence after the desired ceil density has been achieved.
Promoters
The expression vectors must contain promoters which can be used by the host organism for expression of its own proteins. While the lactose promoter system is commonly used, many other well known viral and microbial
promoters have been isolated and characterized, enabling one skilled in the art to use them for expression of HAS and fragments or variants thereof. Transcription Terminators
The transcription terminators contemplated herein serve to stabilise the vector. In particular, those sequences described by Rosenberg et al. (1979) Ann. Rev.
Genet. 13:319-353 are contemplated for use in the present invention.
Non-translated Sequences
It may also be desirable to construct the 3' or 5' end of the coding region to allow incorporation of 3' or 5' non-translated sequences into the gene transcript.
Included among these non-translated sequences are those which stabilize mRNA, as disclosed by Schmeissner et al.
(1984) J. Mol. Biol. 176:39-53. RiboBome Binding Sites
The microbial expression of foreign proteins requires operational elements which include ribosome binding sites. A ribosome binding site is a sequence which a ribosome recognizes and binds to in the initiation of protein synthesis as set forth in Gold et al., Ann. Rev. Microbiol. 35:557-580 and Marquis et al. (1986) Gene 42:175-183. A preferred ribosome binding site is GAGGCGCAAAAA(ATG). Leader Sequences and Translational Couplers
Additionally, it is preferred that DNA coding for an appropriate secretory leader (signal) sequence be present at the 5' end of the DNA sequence, as set forth by Watson, M.E. in Nucleic Acids Res. 12:5145-5163, if the protein is to be excreted from the host cytoplasm.
The DNA for the leader sequence must be in a position that allows the production of a fusion protein in which the leader sequence is immediately adjacent to and covalently joined to HAS, i.e., there must be no transcription or translation signals between the two DNA coding sequences.
In some species of host microorganisms, the presence of an appropriate leader sequence will allow transport of the completed protein into the periplasmic space, as in the case of some E. coli . In the case of certain E. coli , Saccharomyces and strains of Bacillus and Pseudomonas, the appropriate leader sequence will allow transport of the protein through the cell membrane and into the extracellular medium. In this situation, the protein may be purified from extracellular protein.
An additional DNA sequence can be located immediately preceding the DNA sequence which codes for
HAS. The additional DNA sequence is capable of functioning as a translational coupler, i.e., it is a DNA sequence that encodes an RNA which serves to position ribosomes immediately adjacent to the ribosome binding site of the inhibitor RNA with which it is contiguous. The translational coupler may be derived using the DNA sequence TAACGAGGCGCAAAAAATGAAAAAGACAG CTATCGCGATCTTGGAGGATGATTAAATG and methods currently known to those of ordinary skill in the art related to translational couplers.
Translation Terminators
The translation terminators contemplated herein serve to stop the translation of mRNA. They may be either natural, as described by Kohli, J., Mol. Gen,
Genet. 182:430-439, or synthetic, as described by
Pettersson, R.F, (1983) Gene 24:15-27.
Selectable Markers
Additionally, it is preferred that the cloning vector contain a selectable marker, such as a drug resistance marker or other marker which causes expression of a selectable trait by the host microorganism. In one embodiment of the present invention, the gene for ampicillin resistance is included in the vector. In other plasmids, the gene for tetracycline resistance or the gene for chloramphenicol resistance can be included.
Such a drug resistance or ether selectable marker facilitates the selection of transformants. Additionally, the presence of such a selectable marker in the cloning vector may be of use in keeping contaminating microorganisms from multiplying in the culture medium. A pure culture of the transformed host microorganisms would be obtained by culturing the microorganisms under conditions which require the induced phenotype for survival.
The operational elements discussed herein are routinely selected by those of ordinary skill in the art in light of prior literature and the teachings contained herein. General examples of these operational elements are set forth in B. Lewin (1983) Genes, Wiley & Sons, New York. Various examples of suitable operational elements may be found in the vectors discussed above, and may be gleaned via review of the publications discussing the basic characteristics of the aforementioned vectors.
Upon synthesis and isolation of all the necessary and desired component parts, the vector can be assembled by methods generally known to those of ordinary skill in the art. Assembly of such vectors is within the ordinary skill in the art, and, as such, is capable of being performed without undue experimentation.
Multiple copies of the DNA sequences of the present invention and their accompanying operational elements may be inserted into each vector. In such case, the host organism would produce greater amounts per vector of HAS. The number of multiple copies of the DNA sequence which may be inserted into the vector is limited only by the ability of the resultant vector, due to its size, to be transferred into and replicated and transcribed in an appropriate host cell.
Other Host Microorganisms and Cells
Vectors suitable for use in microorganisms other than E. coli are also contemplated for use in the present invention. Such microorganisms include, for example, Streptococci, Bacillus, Pseudomonas,
Salmonella, Serratia, and yeast.
Also contemplated within the scope of the present invention is the expression of HAS in vertebrate or invertebrate cells, including, for example, Chinese Hamster Ovary cells, VERO cells, HeLa cells, WI38 cells, EHK cells, COS cells, and MDCK cells, as well as insect cells, such as those of Spodoptera frugiperda .
For expression in Bacillus, preferred vectors should include a regulated promoter such as the alpha amylase promoter, the subtilisin promoter, the P-43 promoter, or the spac-126 promoter. Useful transcription terminators include rrn and rrn BT.T. Tramscriptional start sites and leader peptides can be chosen from among those from E . amyloliquefaciens neutral protease, B. amyloliquefaciens alpha-amylase, and B. subtil is subtilisin. Useful antibiotic markers are Kanr and Camr. Ribosome binding sites can be obtained from the B , amyloliquefaciens neutral protease and B. amyloliquefaciens alpha-amylase genes. A preferred expression system in hosts of the genus Bacillus
involves the use of plasmid pUB110 as the cloning vehicle.
For expression in Pseudomonas, promoters can be selected from Trp, Lac, and Tac. Useful transcriptional start sites and leader peptides can be obtained from the phospholipase C and exotoxin A genes. Useful antibiotic markers are those for sulfonamides and streptomycins. A useful ribosome binding site can be obtained from the Trp promoter of E. coli . Particularly preferred vectors would employ the plasmid RSF1010, and derivatives thereof.
In the case cf yeast, useful promoters include Gal 1 and 10, Adh 1 and 11, and Pho 5. Transcription terminators can be chosen from among Cyc, Una, Alpha Factor, and Sac 2. Transcriptional start sites and leader peptides can be obtained from the invertase, acid phosphatase, and Alpha factor genes. Useful selection markers are Ura 3, Leu 2, His 3, and Tap 1.
Finally, in the case of expression in mammalian cells, the DNA encoding HAS should have a sequence efficient at binding ribosomes. Such a sequence is described by Kozak in Nucleic Acids Research (1987) 15:8125-6132. The HAS-encoding fragment can be inserted into an expression vector containing a transcriptional promoter and a transcriptional enhancer as described by
Guarente in Cell (1988) 52:303-305 and Kadonaga et al.
(1987) Cell 51:1079-1090. A regulatable promoter as in the Pharmacia plasmid pMSG can be used, if necessary or desired. The vector should also possess a complete polyadenylation signal as described by Ausubel et al. (1987) in Current Protocols in Molecular Biology, Wiley, so that mRNA transcribed from the vector is properly processed. Finally, the vector may also contain the replication origin and at least one antibiotic resistance marker from a plasmid such as pBR322, to
allow replication and selection in E. coli .
In order to select a stable cell line that produces
HAS as described herein, the expression vector can carry the gene for a selectable marker such as a drug resistance marker or a complementary gene for a deficient cell line, such as a dihydrofolate leduccase
(dhfr; gene for transforming a dhfr cell line, as described by Ausubel et al., supra. Alternatively, a separate plasmid carrying the selectable marker can be cotransformed along with the expression vector.
Vectors for mammalian cells can be introduced therein by several techniques, including calcium phosphate:DNA coprecipitation, electroporation, or protoplast fusion. Coprecipitation with calcium phosphate as described by Ausubel et al., supra, is the preferred method.
Preferred vectors include, for example, a PSVT7 eukaryotic expression plasmid. EXAMPLE 1
Isolation of a λgt11 clone expressing HAS
A genomic library was constructed using DNA of Streptococcus equisimilis D181. The genomic DNA was partially digested with the restriction enzyme AluI, and the fragments ranging in size from 2 to 4.5 kb were isolated by sucrose gradient centrifugation (J.H. Weis in Current Protocols in Molecular Biology. F.M. Ausubel et al., eds., 1989). The isolated fragments were dephosphorylated, methylated with EcoRI methylase, and bound to EcoRI linkers (Wu et al., 1987, in Guide to Molecular Cloninσ Technigues, S. Berger et al., eds., Academic Press, San Diego). The linker-containing DNA was digested with EcoRI, separated from the other fragments, ligated to λgtll DNA, and packaged in infectious virions using the "one-strain-packaging"
system SMR10 described by Rosemberg et al. (Gene, 1985, 38: 165-175) The packaged DNA was used to transfect E. coli Y1089 (Stratagene). The library was screened using polyclonai antibodies directed against HAS, previously affinity purified on the protein itself immobilised on CNBr-Sepharose. Cross-reactive antibodies to E. coli/λgtll lysates were removed as described by Sambrook et al. Positive clones were identified on plates without using the lacZ inducer, IPTG, as described by Huynh et al. (1986, in DNA Cloning; A Practical Approach. D.M Glover, ed., Vol. 1, IRL Press, Oxford, England), indicating that the recombinant clones contained a promoter functioning in E. coli . Ten clones were isolated from 50,000 lysis plaques. These clones were purified and amplified as described in Sambrook et al. Proteins were extracted with chloroform/methanol.
Following electrophoresis on a polyacrylamide gels in the presence of SDS (SDS-PAGE) and Western blotting, clones expressing the entire HAS protein were identified and isolated. One of these clones expressed two proteins, of about 52 and 56 kDa, which were recognized by the antibodies (Fig. 1, B). A similar protein pattern was observed in protoplastic membranes extracted from the streptococci (Fig. 1, A). The proteins of the λtll lysate (Fig. 1, C) were not recognized by the antibodies. This clone, designated λgtll/2LK, containing a DNA insert of about 3.1 kb, was selected, ana when digested with EcoRI, generated fragments of 2.1, 0.33 and 0.67 kb (Fig. 2). The 2.1 kb fragment expressing HAS was subcloned in λgtll to generate λgtll/2LK-D, which was used for subsequent analysis. A deposit thereof has been made at the DSM.
EXAMPLE 2
Amino acid sequence analysis
HAS was purified from both S. equisimil is D181 and λgtll/2LK lysatea as described by Prehm and Mausolf (Biochem. J., 235: 887-889, 1986). Purified HAS (200 μg) was dissolved in 200 μi of 6 M urea, diluted with 400 μl of 20 mM Tris-HCl, pH 7.8, and digested with 5% trypsin or V8 -protease for 24 hours. The mixture was acidified with trifluoroacetic acid and the peptides centrifuged at 10,000 rpm for 3 minutes. The supernatant was applied to a C18 reverse-phase HPLC column (VYDAC 218 TP54). Peptides were eluted in 30 minutes with a linear gradient from 0.1% trifluoroacetic acid in water to 0.1% trifluoroacetic acid in 70% acetonitrile with a flow rate of 1 ml/min. Elution was monitored at 220 nm. The fractions were dried and analyzed in a gas phase sequencer. The proteolytic fragments of the synthase, both recombinant (λgtll/2LK) and from streptococci, were isolated and analyzed. The same sequence was found in the two preparations, indicating that the recombinant protein was indeed HAS.
EXAMPLE 3
Nucleotide sequence analysis
The double-stranded DNA was isolated from λgtll/2LK-D by Manfiolette's method (Manfiolette et al., Nuc. Acids Res.. 1988, 16: 2873-2884). It was not possible to subclone the whole 2.1 kb fragment in plasrcids such as pGEM-3Z or 7Z (Promega, Madison, WI, USA), pUC-18 (New England BioLabs, Beverly, MA, USA) or pBluescript SR+ (Stratagene, La Jolla, CA, USA), which would have allowed the determination of the nucleotide sequence by a conventional strategy. The insert cloned in E. coli was always shorter than the original. It was, however, possible to subclone the right-hand fragment of
about 1.27 kb from the XbaI site to the EcoRI site (see Fig. 2) in pGSMR-7Z, indicating that the region en the left of about C.86 kb was responsible for the plasmid instability. The XbaI -EcoRI fragment was subcloned into smaller fragments and the sequence was determined by plasmid sequencing. The left hand portion of λgtll/2LK-D was sequenced by using a number of different approaches. The extreme left hand part was sequenced on the λgtll/2LK-D DNA itself using an fmol DNA sequencing kit (Promega), primer 2 (5'-TTGACACCAGACCAACTGSTAATG-3') labelled with 32P, and linear amplification. Briefly, 17 μl of reaction mixture containing 150 ng of λgtll/2LK-D DNA, 50 mM Tris-HCl, pH 9.0, and 2 mM MgCl, were mixed with a suitable mixture of d/ddNTP, covered with mineral oil, and exposed to 30 cycles of Polymerase Chain Reaction (PCR) (30 seconds at 95°C, 30 seconds at 65°C) after initial denaturation at 95°C for 2 minutes. Further sequence information was obtained from the λgtll/2LK insert of about 3.1 kb which had been amplified by PCR, using primers flanking the EcoRI cloning site (primer 1: 5'-GGTGGCACGACTCCTGGAGCCCG-3'; primer 2). Initial denaturation at 95°C for 2 minutes was followed by 35 cycles at 95°C for 1 minute, 45°C for 1 minute, and 72°C for 5 minutes. The product of this amplification was sequenced using primers from the inner sequence of HAS (primer 3: 5'-AGGAATGTCACAACCT-3'; primer 4: 5 '-CCCCTAGAGAGTCTAGA-3'). Thirdly, λgtll/2LK-D DNA was sequenced directly according to Snyder's modified protocol (Snyder et al., Meth. Enzymol. , 1987, 154: 107-128). Five μg of DNA were digested with KpnI and SacI, extracted with phenol, precipitated with ethanol, and resuspended in 20 μl cf water. The DNA was denatured with 2 μl of 2 M NaOH, 2 mM EDTA for 10 minutes at 37°C. It was then precipitated with 13 μl of 1.5 M Na acetate and 2.5 volumes of ice
cold ethanol (~20°C), and left in a bath of methanol and dry ice for 10 minutes. After centrifugation, the DNA was resuspended in 13 μl of 7.5 mM Tris-KCl, 7.5 mM dithiothreitol, 5 mM MgCl2, pH 7.5, 0.7 ng of primers 1 or 2, labelled with 32P, and incubated at 55°C for 15 minutes. Thereafter, the protocol described for the piasmidic DNA sequence was followed. Finally, restriction fragments of λgtll/2LK generated by digestion with the enzymes NdeI , Nhel and Rsal were cloned in plasmids and sequenced according to the protocol described. The sequenced fragments are shown in Fig. 2. The amino acid sequence derived from the nucleotide sequence was compared to that of the HAS peptides, and the two proved to be identical.
Figure 3 shows the complete streptococcal HAS nucleotide sequence and that of the flanking regions with their amino acid sequences. The sequences obtained from the isolated peptides are underlined. Starting from the ATG codon corresponding to nucleotides 349-351, there is an open reading frame of 1566 bp, terminating with a TAG codon at nucleotides 1934-1936. This fragment of DNA can encode a protein of 522 amino acids with an Mr of 56,624. Despite the presence of an ATG codon in position 424-426 which could itself correspond to an initiation codon, the 349-351 codon is probably correct. Indeed, it possesses a Shine-Delgamo sequence (GGAAGG) 4 bp before the initiation ATG, very similar to the sequence linked to the ribosomes seen in other Gram positive bacteria. A possible promoter for Gram positive bacteria has been identified, shown as an unbroken line above the sequence in Fig. 3, at -35 and -10 (TATACA and TAAAAT), with an ideal space of 16 bp. The region immediately before the start is rich in AT (74% vs 57% in the encoding region) in a manner that is characteristic of a promoter region of Gram positive
bacteria. Within this AT-rich region there are two inverted sequences (Fig. 4) which could be functional in regulating gene expression. At the end of the complete encoding sequence are two additional inverted sequences (Fig. 4) which could form a potential loop of 1653 bp. Three palindromic sequences are also shown, two inside the encoding region and one after the terminal TAG codon (shown in Fig. 3 as a broken line above the sequence), the function of which is as yet unknown. Streptococcal HAS has been found in protoplastic membranes. It is therefore to be expected that the mature protein is preceded by a signal peptide.
EXAMPLE 4
Hydrophobic profile of HAS
Figure 5 shows the hydrophobic profile of HAS. Starting from the initiation ATG, the first 33 amino acids have the characteristics of a typical bacterial "leader" sequence (Vlasuk et al., J. Biol. Chem.. 1983, 258: 7141-7148): a portion of 12 basic amino acids followed by a hydrophobic core of 14 amino acids terminating with 7 hydrophilic amino acids. There is a putative cleavage site at amino acid 35 for the removal of the signal peptide, whose 3.5 kDa could reduce the molecular weight of the processed protein from 56 kDa to 53.1 kDa. This is the weight determined in previous studies (Prehm and Mausolf, Eiochem. J., 1986, 235: 887-889) and, indeed, different quantities of the processed and wild forms have been found in protoplastic membranes of streptococci and in λgtil/2LK lysates in E. coli (Fig. 1). Therefore, the cleavage of the signal peptide from HAS explains the two forms of the protein observed in the Western blot in Fig. 1.
EXAMPLE 5
Southern blotting analysis in other streptococci
Southern blotting experiments were, carried out to determine whether the gene encoding HAS is conserved in other HA-producing streptococci. Five μg of genomic DNA digested with various restriction enzymes (Fig. 6) were subjected to electrophoresis in a 1% agarose gel. The DNA was then depurinated (0.25 N HCl for 10 minutes, twice), denatured (1.5 M NaCl, 0.5 M NaOH for 25 minutes, twice), neutralized (1 M Tris-HCl, pH 6.5, 2 M
NaCl for 30 minutes, twice), and lastly transferred overnight from the gel to a nylon Hybond-N membrane
(Amersham, England) by the Southern blotting technique.
The DNA was then fixed to the membrane by exposure to UV irradiation for 3 minutes. A "DIG Non-radioactive DNA Labeling and Detection Kit" (Boehringer Mannheim, Germany) was used to label the probe and in subsequent stages of the experiment, following the manufacturer's instructions. The various purified fragments (about 400 ng each) used as probes were labelled in a non-radioactive fashion by random priming at 37°C for 1 hour. The filters onto which the DNA had been transferred were prehybridized in at least 20 ml of hybridization solution (5xSSC, 1% w/v blocking reagent, 0.1% w/v N-laurosylsarccsine sodium salt, 50% formamide) for 2 hours at 42°C, and then hybridized overnight at the same temperature following addition of the labelled, denatured probe to the solution. The filters were then washed and developed. The results are shown in Fig. 5.
The DNA of all three HA-producing strains (S. equi , S. zooepidemicus, and S. equisimiliB) hybridized with the probe containing the entire insert of 3.1 kb of λgtll/2LK (Fig. 6A), while the result was negative with the S. sanguis strain which does not in fact produce HA. Surprisingly, numerous bands were observed in lanes
containing the S . equisimilis DNA, indicating the presence of numerous copies of the DNA sequence used as a molecular probe. Two other probes were used to determine whether this phenomenon was correlated with the HAS gene or with DNA regions flanking it: these were the flanking EcoRI fragment of 0.67 kb and tne XbaI - PstI fragment inside the HAS coding region. The results are shown in Figs. 6B and 6C. The unexpected pattern was observed only with the first probe and only in S. equisimilis D181. In the other HA-producing strains tested, the probe containing the entire gene showed similar behavior and hybridized with a single fragment.
These results indicate that the HA synthase gene, or genes homologous thereto, are conserved in all the streptococcal strains analyzed, thus demonstrating the importance thereof in HA synthesis. The HAS genes of streptococcal strains can be isolated by employing the 3.1 kb insert of λgtll/2LK, or fragments thereof, as probes by techniques well known in the art. The repetitive profile observed in D181 suggests that the HAS gene is flanked by a DNA segment peculiar to this organism and of which 5 -10 copies are to be found within the chromosome. This could be an insertion sequence or a transposon.
EXAMPLE 6
Construction of an expression vector for HAS synthesis The identification of promoters active in Lancefield's group C streptococci has been described in Italian patent application No. PD92A000109 filed on 19 June 1992. One of the promoter fragments found to be active in this study which contains the λpL and pR promoters in tandem was used to construct an expression vector for HAS as outlined below. Obviously, any expression vectors containing promoter sequences active
in streptococci, E. coli , other bacterial species, or eukaryotic cells can be used in the construction of plasmids for the overexpression of HAS.
The HAS encoding fragment could net be cloned directly from λgtll/2LK-D due to the presence of unsuitable internal restriction sites. Therefore, attempts were made to introduce suitable restriction sites at both ends of the fragment by PCR amplification of the insert with oligonucleotides containing Ba mHI sites (primer F11: 5'-TTGGATCCGCGACGACTCCTGGAGCCCG-3' and primer R12: 5 '-TTGGATCCCACCAGACCAACTGGTAATG-3' ). The fragment was amplified successfully using λgtll/2LK-D as template and the following amplification protocol: 1 cycle of 2 min 94°C, 2 min 45°C, 5 min 72°C followed by 34 cycles of 1 min 94°C, 2 min 34°C, 5 min 72ºC. Unfortunately, all attempts to clone the entire amplified fragment in plasmid vectors failed, suggesting a possible toxic effect of the protein in E. coli or the presence of streptococcal sequences that could cause plasmid instability. The amplified fragment was digested with the restriction enzyme Xbal, and the right-hand part of the fragment (from the unique internal XbaI site to the end) was cloned, yielding the plasmid pY05. The cloning strategy is outlined in Fig. 7, In order to clone the left-hand segment, the primers ST2 and ST3 were used. These primers have the following sequences: ST2 : 5'-CTCTCGAGTTAGGAGGAAGGTCATATGACAGTA-3'; ST3: 5'-CCTAGAGTCTAGATCAGGATTTT-3'. 3T2 is located at the beginning of the HAS coding sequence and includes the ribosome binding site and an artificially inti-oduced Xhol site to facilitate subsequent cloning. ST3 is located near the internal Xbal site of the cloned insert. These primers were used to amplify a DNA fragment from λgtll/2LK using the following protocol: 35 cycles of 1 min 95ºC, 1 min 45°C, 1 min 70°C. The
amplified fragment was subsequently purified and digested with the restriction enzymes XbaI and XhoI. The purified fragment was digested with XhoI-XbaI, re-purified, and ligated with the purified Xbal -BamHI fragment from pYO5 and XhoI-BamHI digested pGEM-7Z, and transformed into E. coli HB101 (Promega) to yield plasmid pY011 (Fig. 8). Since the insert of pY011 was derived entirely from PCR amplification and, therefore, might contain some mutations, as much of the insert as possible was replaced with DNA derived directly from genomic cloning. The Nhel -EcoRI fragment of λgtll/2LK, which contains most of the HAS coding sequence, was subcloned into plasmid pGEM4 to yield pY012 (Fig, 9). The HindII fragment of pY011 was subsequently replaced by the corresponding fragment of pY012 as outlined in Fig. 9 to yield plasmid pY014. The HAS encoding sequence was placed under the transcriptional control of the λpLpR promoters, as outlined in Fig. 10, by carrying cut a triple ligation containing the Xhol-EcoRI fragment of pY014, an XhoI -BamHI fragment from plasmid pGEM-λpromBamHI containing the λpLpR promoters and the cI857 repressor gene, and BamHI-EcoRI digested pCK17, a cloning vector derived from a cryptic lactococcal plasmid (Anderson et al., 1985, FEMS Microbiol. Lett., 30: 193-196). The resulting HAS expression vector was designated pY016.
Plasmid pY016 does not contain any transcription terminators downstream of the HAS gene. Since it is possible that the presence of terminators may have a positive effect on cloned gene expression by giving rise to more stable mRNA, transcription terminators were added to pY016 in the following manner. The EcoRI-NarI fragment of plasmid pJLA501 (Medac) containing the E. coli fd terminators, was ligated to EcoRI- ClaI digested pY016, and the ligation mix was transformed into E. coli
HB101 to yield pY019 as outlined in Fig. 11.
EXAMPLE 7
Controlled expression of HAS in E. coli
Plasmids pYC16 and pY09 (the expression vector not containing the HAS encoding gene) were introduced into E. coli ED8739 (Murray et al., Mol. Gen. Genet., 150: 53-61, 1977) by transformation, and transformants were selected on LB agar medium containing 20 μg/ml of chloramphenicol (Cm). It is well known that the activity of the λpLpR promoters is blocked by the temperature sensitive repressor cI857 at 30°C, but that the repressor is inactivated at 37°C or above, thus allowing expression of genes under control of the promoters.
To determine if expression of the HAS gene was thermoinducible, E. coli ED8739 containing pY016 or pY09 was grown in LB containing Cm (20 μg/ml) at 30°C overnight and subcultured into 2 separate LB cultures which were subsequently incubated at 30 and 42°C for 3h. An aliquot of 1 ml of each culture was transferred to a 1.5 ml Eppsndorf tube, and the cells were pelleted by centrifugation at 15,000xg for 30 sec. Total proteins were extracted by resuspending the pellet in 0.5ml of extraction buffer (2% SDS, 5% (8-mercaptoethanol) and heating tc 95°C for 3 min. The samples were centrifuged for 3 min at 15,800xg, aliquots of 40 μl of each supernatant were loaded on a 10% polyacrylamide gel, and proteins were separated by electrophoresis at 13mA for 16h. The proteins were transferred to nitrocellulose by Western blotting. Detection of HAS was carried cut using polyclcnai rabbit antibodies raised against a synthetic peptide (sequence: RADAKGKLQPDLAEKVDVSE) corresponding to amino acids 76-95 of the HAS sequence (see Fig. 3). The results are shown in Fig. 12.
E. coli ED8739 containing the expression vector pY016 grown at 42ºC (lane 2b) gives rise to two protein bands of the same size as those observed in the original λgtll/2LK clone (lane λ+). Estimation of the total amount of protein produced indicates that HAS corresponds to about 10% of total cellular protein. The presence of the two forms of KA synthase indicates that the signal sequence is also cleaved efficiently from the protein produced by pY016.
EXAMPLE 8
Production of HA by recombinant strains of 9. equi 68222 containing HAS expression vectors
To determine if the presence of HAS expression vectors in S. equi 68222 results in an increase in HA production with respect to the wild-type strain, S. equi 68222 containing the plasmids pY09, pY016 or pY019 were compared with respect to the quantity of HA produced. Plasmid pY09 was the negative control as it contains only the λpLpR promoters and the repressor gene, but not the HAS encoding gene. Plasmids pY09, pY016. and pY019 were transformed into S. equi 68222 by electroporation. The basic procedure was as fellows: Overnight cultures grown in BHI medium at 37°C in a shaking incubator were diluted 10-fold in fresh medium containing 6,000 units of hyaluronidase per liter and grown under the same conditions until they reached an OD600 of approximately 0.5, which corresponds to the mid-exponential phase of growth. The culture was chilled on ice for 10 minutes and the cells were subsequently pelleted by centrifugation at 5,000 rpm for 10 min. The cells were washed twice with an equal volume of ice-cold distilled water and subsequently resuspended in ice-cold distilled water to obtain a final OD600 of about 50. An aliquot of 50 μl of this cell suspension was mixed in an Eppendorf
tube with 1-2 μl of plasmid DNA solution at a final concentration of 100 μg/ml. The mixture was transferred to an electroporation cuvette with a spacing of 0.2 mm, inserted in a Genepulser, and subjected to an electric pulse under the following conditions: voltage, 12.5 kv/cm, resistance 200 ohms, capacitance 25 μF. The samples were immediately diluted in 1 ml of fresh BHI medium and incubated for 1-2 h at 37°C to allow plasmid gene expression. To select transformed cells, aliquots of the transformation mixture were plated on BHI plates containing 5 ug/ml Cm. The plates were incubated at 37°C, and transformants appeared within 24-48 h.
Mucoid colonies of S. equi 68222 containing pY09, pY016 or pY019 were inoculated from BHI agar plates containing 5 μg/ml Cm into a small volume of BHI plus Cm in Erlenmeyer flasks and grown overnight, on a rotating incubator at 37°C. These overnight cultures were diluted 10-fold in fresh medium containing, in addition, glucose at a final concentration of 2% and the acid-base indicator phenol red at a final concentration of 5 mg/l. The phenol red turns yellow when the culture broth becomes acidic due to the production of lactic acid by the streptococci. Since acidic conditions inhibit bacterial growth and HA production, once a yellow colour is observed in the culture medium, a sufficient quantity of 3 N NaOH must be added to raise the pH to neutrality. The cultures were incubated at 37°C in a rotating incubator and samples were taken at regular intervals to follow growth and HA production. Growth was followed by measuring the OD600 of the samples. The HA was precipitated from the culture broth by the addition of two volumes of ethanol, and the precipitate was resuspended in an equal volume of distilled water. The HA concentration was measured by the method of Blumenkrantz and Absoe-Kansen (Anal. Biochem., 54:
484-489, 1973).
The results are shown in Fig. 13 and Table 1. The strains containing pY016 and pY019 produced higher levels of HA compared to the strain containing pY09, indicating that the presence of multiple copies of the HAS encoding gene favours the more efficient production of HA. When the quantity of polymer is calculated with respect to the culture OD, it becomes evident that the pY016 and pY019 strains had accumulated approximateiy 1.4-1.5 times more HA than the pY09-containing strain at the end of the cultivation period.
It will be obvious to those proficient in the art that the culture conditions can be varied significantly with respect to growth medium and culture conditions while still obtaining a positive effect on the over-expression of the HAS gene.
EXAMPLE 9
Industrial applications of the HAS gene
As demonstrated by the results of Examples 7 and 8, recombinant prokaryotic cells harboring an expressible DNA sequence encoding HAS can be produced which, when grown under appropriate conditions, produce elevated levels of HAS or hyaluronic acid.
In a similar manner, employing techniques well known in the art as described above, vectors for the expression of HAS in eukaryotic cells, such as mammalian cells and insect cells, can also be constructed.
Such recombinant prokaryotic or eukaryotic cells harboring an expressible DNA sequence encoding HAS can be employed as industrial sources of HAS and/or hyaluronic acid. By cuituring these cells under appropriate conditions, it will be possible to recover HAS, hyaluronic acid, or both from the cells themselves, from the culture medium, or from both.
EXAMPLE 10
Purification of HAS
In order to achieve in vitro synthesis of HA and exploit the advantages described above, it was necessary to develop a fast and simple method for the purification of active HAS.
HAS can be purified according to the following protocol:
1. Streptococcus equisimilis D181, or any alternative cells capable of producing HA such as
related Lancefield's group A or C streptococcal species or recombinant organisms expressing HAS, is grown in the desired volume of Todd-Hewitt broth or any ether suitable nutrient medium at a temperature retween 50 and 40°C, but preferably at 37°C, to a final OD600 greater than 0.1, and preferably about 0.5. Approximately 1 h before cell harvesting, 6,000 units per liter of hyaluronidase can be added to degrade any KA produced.
2. The bacteria are harvested by centrifugation, washed at least two times with a suitable buffer such as cold phosphate buffered saline (PBS), and resuspended in a final volume of between 100 and 1,000 ml, but preferably in 200 ml, of PBS containing approximately 1 mM dithiothreitol.
3. This suspension is subjected to procedures designed to cause cell disruption, such as sonication at 0°C, under conditions sufficient to ensure complete cell disruption while minimizing enzyme inactivation. A wide range of sonication conditions can be used, but those preferred are 15 min. at 120 watts. Subsequent operations are carried out at 4°C.
4. Bacterial debris is removed by centrifugation, and the supernatant is subjected to ultracentrifugation under conditions capable of sedimenting the bacterial membranes, preferably at 40,000 rpm for 30 min.
5. The sediment, which contains the streptococcal membranes, is suspended in a small volume of 50 mM Trismalonate buffer, or any other suitable buffer, containing approximately 1 mM dithiothreitol, by sonication under mild conditions, for example 30 sec. at 20 watts. The protein concentration is determined, and the suspension is diluted in the same buffer to a final protein concentration of between 1 and 10 mg/mi, but preferably at 3 mg/ml.
6. To extract HAS from the bacterial membranes, a 10% solution of a mild detergent such as digitonin is added to the sample to give a final concentration of between 0.5 and 2%, but preferably 1%. The suspension is stirred in order to ensure thorough mixing for approximately 1 hour, and subjected to ultracentrifugaticn in order to separate membrane fragments at 40,000xg for 30 min. or other similar conditions.
7. To achieve separation of the synthase from the detergent phase, a number of strategies can be used, but that preferred is the procedure previously described by Parish et al. (Anal., Biochem., 1986, 156:495-502) where phase separation is achieved in certain detergents by the addition of polyethylene glycol (PEG) 5000. To ensure that the synthase separates into the aqueous phase, the protein can be "loaded" with newly synthesized HA to increase its affinity for the aqueous phase.
Therefore, to 5 ml of the supernatant from step 6 the following compounds are added: 1 ml of a 50% solution of PEG 6000, between 0.025 and 0.1 ml, but preferably 0.05 ml, of a 1 M solution of MgCl2, between 0.5 and 5 mg, but preferably 2 mg each, of UDP-N-acetylglucosamine and UDP-glucuronic acid. The mixture is incubated under conditions suitable for the synthesis of HA, for example at 37°C for 30 min., and is subsequently rapidly cooled to 0°C in an ice/salt bath. An additional aliquot of 1 ml of 50% PEG 6000 is added, and the solution is vortexed. The solution becomes turbid, indicating that phase separation has taken place.. The suspension is again subjected to ultracentrifugation, for example at 40,000 rpm, for 30 min.
8. in order to separate active HAS from the above mixture, a large number of approaches can be used, including HPLC chromatography. Preferably, the supernatant is subjected to HPLC on an ion-exchange column such as a Waters DSAE-protein Pak 5PW, 7.5 mm × 7.5 mm, which has been equilibrated with a suitable buffer such as 50 mM Tris-maionate buffer, pH 7.0, containing a detergent such as digitonin at a final concentration of about 0.5%. The sample is pumped onto the column at the desired flow rate, preferably at the rate of 1 ml/min. Following loading of the supernatant, the column is washed with the starting buffer, and proteins can be eluted by progressively increasing the salt concentration of the buffer, for example from 0 to 0.5 M, in 30 min. with a constant flow rate of iml/min. Fractions of the desired volume can be collected; a volume of 1 ml is suitable.
9. To identify the fractions containing active HAS, a number of determinations are carried out on each fraction. These include: absorbance at 280 nm, conductivity, and HAS activity as determined using radiolabelled precursor as described previously by Prehm (Biochem. J.. 1983, 211:181-189). In order to associate the HAS activity with a certain protein, the protein pattern of each fraction can be analysed by polyacrylamide gel electrophoresis following precipitation of the proteins from a fixed volume of each fraction, for example 200 μl, by standard techniques such as that described by Wessel and Flugge (Anal. Biochem., 1984, 138:141-143).
The results of two independent experiments are shown in Figs. 14 and 15. In both cases, the peak of HAS activity resides in fractions containing an essentially pure protein of approximately 56 kDa, which corresponds to the HAS described above.
These results prove that the 56 kDa protein constitutes the active synthase, and is sufficient to facilitate the synthesis in vitro of HA having characteristics superior to the HA presently isolated from animal or bacterial sources.
EXAMPLE 11
In vitro production of hyaluronic acid of varying molecular weight using purified HAS
Hyaluronic acid of varying molecular weight for different applications can be synthesized in vitro using purified HAS.
A typical protocol is as follows:
1. In a reaction vessel of desired volume, purified HAS is diluted in 50 mM Tris-malonate buffer, or any other suitable buffer, to a final protein concentration of between 0.01 and 1.0 mg/ml, but preferably at 0.1 mg/ml. To the solution, dithiothreitol to a final concentration of approximately 1 mM, MgCl2 to final concentration of approximately 10 mM, UDP-GlcA and UDP-NAcGlc both in concentrations to between 0.1 and 5 mM, but preferably to 1 mM, are added.
2. The mixture is incubated under conditions suitable for the synthesis of HA, for example at 37°C for 4 hours, and subjected to gel filtration on a Sephacryl S-1000 (83 cm × 1 cm) column or any other suitable column. The HA is eluted with PBS or any other suitable buffer.
3. To identify the molecular weight of the HA produced according to steps 1 and 2, radiolabelled precursors are used as described previously by Prehm
(Biochem. J.. 1983, 181-189). The same conditions for incubation of the mixture and gel filtration are used as described in step 2. Fractions of the eluted material are collected in volumes between 0.1 ml and 2 ml, but
preferably 0.58 ml, and aliquots, preferably 0.2 ml, are taken for determination of radioactivity.
The results are shown in Fig. 16. The molecular weight cf the HA synthesized in vitro for 4 hours at 37°C using purified HAS is about 350,000 Da.
The molecular weight of HA synthesized in vitro employing HAS can be varied by varying the incubation period and/or reaction conditions, with the molecular weight varying with varying incubation time ana reaction conditions in the presence of HAS. Those reaction conditions which can be varied to influence the molecular weight of the final HA product include, but are not limited to, pH, temperature, etc. The pH can be varied between 4.2 and 8.9; a decrease in pH results in a decrease in molecular weight of HA. With respect to the effect of temperature, this may be varied between 10 to 40°C; a decrease in temperature results in a decrease in molecular weight of the HA produced.
HA produced in this manner possesses the highly desirable property for pharmaceutical and other related applications that it is extremely pure as compared to HA purified from conventional sources, and does not contain any contaminating proteins, pyrogenic or inflammatory substances, or viruses.
The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and ail such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.
Claims
1. An isolated DNA fragment, comprising a nucleotide sequence encoding hyaluronic acid synthase. 2. The DNA fragment of claim 1, wherein said nucleotide sequence encoding hyaluronic acid synthase is derived from a member of the genus Streptococcus . 3. The DNA fragment of claim 2, wherein said member of the genus Streptococcus is Streptococcus equisimilis D181. 4. The DNA fragment of claim 1, wherein said nucleotide sequence encodes a protein having the amino acid sequence shown in Figure 3. 5. The DNA fragment of claim 1, wherein said nucleotide sequence is the nucleotide sequence shown in Figure 3 from position 349 to position 1917. 6. The DNA fragment of claim 1, wherein said nucleotide sequence comprises a sequence encoding a polypeptide having biological activity functionally equivalent to the amino acid sequence shown in Figure 3.
7. The DNA fragment of claim 6, wherein said DNA fragment is a eukaryotic cDNA. 6. The DNA fragment of claim G, wherein said nucleotide sequence comprises a variant of the nucleotide sequence shown in Figure 3 in accordance with the degeneracy of the genetic code. 9. The DNA fragment of claim 6, wherein said nucleotide sequence comprises a variant, mutant, or fragment of the nucleotide sequence shown in Figure 3 encoding a polypeptide containing at least one amino acid substitution, addition, or deletion, or a combination of any two or more thereof. 10. The DNA fragment of claim 2, wherein said member of the genus Streptococcus belongs to group A or group C. 11. A recombinant expression vector, comprising a nucleotide sequence encoding hyaluronic acid synthase, wherein said vector is capable of expressing said hyaluronic acid synthase in a transformed prokaryotic or eukaryotic cell. 12. A recombinant expression vector, comprising a nucleotide sequence encoding hyaluronic acid synthase, wherein said vector is capable of expressing said hyaluronic acid synthase in a transformed prokaryotic or eukaryotic cell, and wherein said nucleotide sequence is the nucleotide sequence as defined in any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. 13. The recombinant expression vector of claim 11, wherein said nucleotide sequence is the nuclecta.de sequence shown in Figure 3.
14. The recombinant expression vector of claim 13, wherein said vector is a member selected from the group consisting of pY016 and pY019, as shown in Figures 10 and 11, respectively. 15. A prokaryotic or eukaryotic cell transformed with said recombinant expression vector of claim 11. 16. The transformed cell of claim 15, wherein said cell is a member selected from the group consisting of a member of the genus Streptococcus, E. coli , a member of the genus -Bacillus, a member of the genus Pseudomcnas, a member of the genus Salmonella, a member of the genus Serratia , a yeast, a vertebrate ceil, and an insect cell. 17. The transformed cell of claim 16, wherein said vertebrate cell is a member selected from the group consisting of a Chinese Hamster Ovary cell, a VERC cell, a HeLa cell, a WI38 ceil, a BHK cell, a COS cell, and an MDCK cell. 18. The transformed cell of claim 16, wherein said insect cell is a cell of Spodoptera frugiperda . 19. The transformed prokaryotic or eukaryotic cell of claim 15, wherein said cell is capable of expressing hyaluronic acid synthase. 20. The transformed prokaryotic or eukaryotic cell of claim 15, wherein said cell is capable of producing hyaluror.ic acid.
21. A method of producing hyaluronic acid synthase, comprising:
(a) providing a prokaryotic or eukaryotic cell narbcring a DNA sequence encoding hyaluronic acid synthase, wherein said DNA sequence is expressible in said cell;
(b) cuituring said cell in a culture medium; and (c) recovering said hyaluronic acid synthase from said ceil or from said culture medium. 22. A method of producing hyaluronic acid, comprising:
(a) providing a recombinant prokaryotic or eukaryotic cell harboring a DNA sequence encoding hyaluronic acid synthase, wherein said DNA sequence is expressible in said cell;
(b) cuituring said cell in a culture medium; and (c) recovering said hyaluronic acid from said cell or from said culture medium. 23. A method of purifying hyaluronic acid synthase, comprising:
(a) cuituring cells expressing a gene encoding hyaluronic acid synthase;
(b) harvesting said cells of step (a);
(c) disrupting said cells under conditions that minimize the inactivation of hyaluronic acid synthase;
(d) isolating membranes of said cells;
(s) suspending said membranes in a buffer;
(f) extracting said hyaluronic acid synthase from said membranes by adding a detergent to the membrane suspension of step (e), and then centrifuging to produce a detergent phase containing said hyaluronic acid synthase;
(g) adding polyethylene glycoi to said detergent phase of step (f), thereby forming an aqueous phase containing said hyaluronic acid synthase; and
(h) recovering said hyaluronic acid synthase from said aqueous phase of step (g). 24. A method of producing hyaluronic acid of varying molecular weight, comprising:
(a) incubating UDP-GlcA and UDP-NAcGlc with hyaluronic acid synthase under conditions suitable for the synthesis of hyaluronic acid; and
lb) recovering hyaluronic acid,
wherein the molecular weight of said hyaluronic acid can be varied by varying the reaction time and/or reaction conditions under which said UDP-GlcA and said UDP-NAcGlc are incubated in the presence of said hyaluronic acid synthase. 25. Hyaluronic acid produced by the method of claim 24, wherein said hyaluronic acid is free of any contaminating proteins, pyrogenic or inflammatory substances, or viruses.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITPD920110A IT1260153B (en) | 1992-06-19 | 1992-06-19 | IDENTIFICATION OF A DNA FRAGMENT CODING THE HYALURONIC ACID SYNTHETASE (HAS) AND ITS NUCLEOTID SEQUENCE |
ITPD92A000110 | 1992-06-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994000463A2 true WO1994000463A2 (en) | 1994-01-06 |
WO1994000463A3 WO1994000463A3 (en) | 1994-09-29 |
Family
ID=11389978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1993/001575 WO1994000463A2 (en) | 1992-06-19 | 1993-06-21 | Production of hyaluronic acid by transeformed microorganisms |
Country Status (2)
Country | Link |
---|---|
IT (1) | IT1260153B (en) |
WO (1) | WO1994000463A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997040174A1 (en) * | 1996-04-22 | 1997-10-30 | Leukosite, Inc. | Mammalian hyaluronan synthases, nucleic acids, uses thereof |
WO1999023227A2 (en) * | 1997-10-31 | 1999-05-14 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
EP1073460A1 (en) * | 1998-04-02 | 2001-02-07 | The Board Of Regents Of The University Of Oklahoma | Nucleic acid encoding hyaluronan synthase and methods of use |
US6852514B2 (en) | 1994-07-01 | 2005-02-08 | The Board Of Regents Of The University Of Oklahoma | Hyaluronate synthase gene and uses thereof |
US6951743B2 (en) | 1997-10-31 | 2005-10-04 | University Of Oklahoma Board Of Regents | Hyaluronan synthase genes and expression thereof in bacillus hosts |
US6987023B2 (en) | 1998-04-02 | 2006-01-17 | The Board Of Regents Of The University Of Oklahoma | DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use |
US7029880B2 (en) | 1997-07-23 | 2006-04-18 | The Board Of Regents Of The University Of Oklahoma | Streptococcus equisimilis hyaluronan synthase gene and expression thereof in Bacillus subtilis |
US7091008B1 (en) | 1994-07-01 | 2006-08-15 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase genes and expression thereof in Bacillus hosts |
US7094581B2 (en) | 1998-10-26 | 2006-08-22 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthases and methods of making and using same |
US7223571B2 (en) | 1998-04-02 | 2007-05-29 | The Board Of Regents Of The Universtiy Of Oklahoma | Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same |
US7741091B2 (en) | 1998-04-02 | 2010-06-22 | The Board Of Regents Of The University Of Oklahoma | Methods of producing hyaluronic acid and chimeric and hybrid glycosaminoglycan polymers |
WO2013048208A1 (en) * | 2011-09-30 | 2013-04-04 | Ildong Pharm Co., Ltd. | Streptococcus dysgalactiae id9103 and method for production of hyaluronic acid using the same |
WO2013116819A1 (en) * | 2012-02-03 | 2013-08-08 | University Of Rochester | Compositions and methods for recombinant synthesis of high molecular weight hyaluronic acid |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991003559A1 (en) * | 1989-08-29 | 1991-03-21 | Board Of Regents, The University Of Texas System | Dna encoding hyaluronate synthase |
-
1992
- 1992-06-19 IT ITPD920110A patent/IT1260153B/en active IP Right Grant
-
1993
- 1993-06-21 WO PCT/EP1993/001575 patent/WO1994000463A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991003559A1 (en) * | 1989-08-29 | 1991-03-21 | Board Of Regents, The University Of Texas System | Dna encoding hyaluronate synthase |
Non-Patent Citations (3)
Title |
---|
THE BIOCHEMICAL JOURNAL, vol.235, no.3, 1 May 1986, LONDON, UK pages 887 - 889 P. PREHM AND A. MAUSOLF 'Isolation of streptococcal hyaluronate synthase' cited in the application * |
THE BIOCHEMICAL JOURNAL, vol.267, no.1, 1 April 1990, LONDON, UK pages 191 - 196 A. MAUSOLF ET AL. 'Shedding of hyaluronate synthase from Streptococci' cited in the application * |
THE BIOCHEMICAL JOURNAL, vol.289, no.1, 1 January 1993, LONDON, UK pages 179 - 184 M. LANSING ET AL. 'Hyaluronate synthase: cloning and sequencing of the gene from Streptococcus sp.' * |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091008B1 (en) | 1994-07-01 | 2006-08-15 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase genes and expression thereof in Bacillus hosts |
US6855502B2 (en) | 1994-07-01 | 2005-02-15 | Paul H. Weigel | Hyaluronate synthase gene and uses thereof |
US7087413B2 (en) | 1994-07-01 | 2006-08-08 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US8735102B2 (en) | 1994-07-01 | 2014-05-27 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase genes and expression thereof in Bacillus hosts |
US7504246B2 (en) | 1994-07-01 | 2009-03-17 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US7229796B2 (en) | 1994-07-01 | 2007-06-12 | Univ Oklahoma State | Hyaluronan synthase genes and expression thereof in Bacillus hosts |
US7060466B2 (en) | 1994-07-01 | 2006-06-13 | The Board Of Regents Of The University Of Oklahoma | Methods of producing hyaluronic acid using a recombinant hyaluronan synthase gene |
US7166450B2 (en) | 1994-07-01 | 2007-01-23 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US6852514B2 (en) | 1994-07-01 | 2005-02-08 | The Board Of Regents Of The University Of Oklahoma | Hyaluronate synthase gene and uses thereof |
US6991921B2 (en) | 1994-07-01 | 2006-01-31 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US7153677B2 (en) | 1994-07-01 | 2006-12-26 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US7141409B2 (en) | 1994-07-01 | 2006-11-28 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US7115405B2 (en) | 1994-07-01 | 2006-10-03 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US7109011B2 (en) | 1994-07-01 | 2006-09-19 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US7026159B2 (en) | 1994-07-01 | 2006-04-11 | The Board Of Regents Of The University Of Oklahoma | Hyaluronate synthase gene and uses thereof |
US6423514B1 (en) | 1996-04-22 | 2002-07-23 | Millennium Pharmaceuticals, Inc. | Mammalian hyaluronan synthases, nucleic acids and uses thereof |
WO1997040174A1 (en) * | 1996-04-22 | 1997-10-30 | Leukosite, Inc. | Mammalian hyaluronan synthases, nucleic acids, uses thereof |
US7029880B2 (en) | 1997-07-23 | 2006-04-18 | The Board Of Regents Of The University Of Oklahoma | Streptococcus equisimilis hyaluronan synthase gene and expression thereof in Bacillus subtilis |
CN1322121C (en) * | 1997-10-31 | 2007-06-20 | 俄克拉何马大学董事会 | Hyaluronan synthase gene and uses thereof |
EP1522579A3 (en) * | 1997-10-31 | 2007-11-07 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
WO1999023227A3 (en) * | 1997-10-31 | 1999-08-19 | Univ Oklahoma | Hyaluronan synthase gene and uses thereof |
WO1999023227A2 (en) * | 1997-10-31 | 1999-05-14 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US6951743B2 (en) | 1997-10-31 | 2005-10-04 | University Of Oklahoma Board Of Regents | Hyaluronan synthase genes and expression thereof in bacillus hosts |
EP1522579A2 (en) * | 1997-10-31 | 2005-04-13 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses thereof |
US6833264B1 (en) | 1997-10-31 | 2004-12-21 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase gene and uses therof |
JP2001521741A (en) * | 1997-10-31 | 2001-11-13 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ オクラホマ | Hyaluronan synthase gene and uses thereof |
US7604973B2 (en) | 1998-04-02 | 2009-10-20 | The Board Of Regents Of The University Of Oklahoma | DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use |
US7232684B2 (en) | 1998-04-02 | 2007-06-19 | The Board Of Regents Of The University Of Oklahoma | DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use |
US6987023B2 (en) | 1998-04-02 | 2006-01-17 | The Board Of Regents Of The University Of Oklahoma | DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use |
US7741091B2 (en) | 1998-04-02 | 2010-06-22 | The Board Of Regents Of The University Of Oklahoma | Methods of producing hyaluronic acid and chimeric and hybrid glycosaminoglycan polymers |
EP1073460A4 (en) * | 1998-04-02 | 2001-05-23 | Univ Oklahoma | Nucleic acid encoding hyaluronan synthase and methods of use |
US7579173B2 (en) | 1998-04-02 | 2009-08-25 | The Board Of Regents Of The University Of Oklahoma | Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using the same |
US7223571B2 (en) | 1998-04-02 | 2007-05-29 | The Board Of Regents Of The Universtiy Of Oklahoma | Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same |
EP1073460A1 (en) * | 1998-04-02 | 2001-02-07 | The Board Of Regents Of The University Of Oklahoma | Nucleic acid encoding hyaluronan synthase and methods of use |
US7094581B2 (en) | 1998-10-26 | 2006-08-22 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthases and methods of making and using same |
WO2013048208A1 (en) * | 2011-09-30 | 2013-04-04 | Ildong Pharm Co., Ltd. | Streptococcus dysgalactiae id9103 and method for production of hyaluronic acid using the same |
US8986973B2 (en) | 2011-09-30 | 2015-03-24 | Ildong Pharm Co., Ltd. | Streptococcus dysgalactiae ID9103 and method for production of hyaluronic acid using the same |
WO2013116819A1 (en) * | 2012-02-03 | 2013-08-08 | University Of Rochester | Compositions and methods for recombinant synthesis of high molecular weight hyaluronic acid |
US9315588B2 (en) | 2012-02-03 | 2016-04-19 | University Of Rochester | Compositions and methods for recombinant synthesis of high molecular weight hyaluronic acid |
Also Published As
Publication number | Publication date |
---|---|
ITPD920110A1 (en) | 1993-12-19 |
IT1260153B (en) | 1996-03-28 |
ITPD920110A0 (en) | 1992-06-19 |
WO1994000463A3 (en) | 1994-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5922583A (en) | Methods for production of recombinant plasmids | |
RU2129606C1 (en) | STRAIN ESCHERICHIA COLI JM 105 TRANSFORMED WITH PLASMID PAE12 - PRODUCER OF ALPHA-AMIDATING ENZYME, RECOMBINANT PLASMID PAE12, MURINE CELLULAR LINE C127 TRANSFORMED WITH PLASMID PDBPV-MMTNEO α - PRODUCER OF ALPHA-AMIDATING ENZYME, RECOMBINANT PLASMID PDBPV-MMTNEO α | |
RU2072393C1 (en) | Method for obtaining recombination polypeptide possessing growth hormone properties | |
CZ284204B6 (en) | Peptide, nucleic acid molecule, vector, prokaryotic host cell and process for preparing nfg polypeptide | |
JPH04502916A (en) | Purified ciliary neurotrophic factor | |
WO1994000463A2 (en) | Production of hyaluronic acid by transeformed microorganisms | |
Kuo et al. | Cloning and expression of the cDNA for a Drosophila insulin-degrading enzyme | |
Bliss et al. | Polysialic acid export in Escherichia coli K1: the role of KpsT, the ATP-binding component of an ABC transporter, in chain translocation | |
Engel et al. | Murein-metabolizing enzymes from Escherichia coli: existence of a second lytic transglycosylase | |
KR0159107B1 (en) | Protein with urate oxidase activity, recombinant gene coding therefor, expression vector, micro-organisms and transformed cell | |
WO1991018101A1 (en) | Process for producing protein | |
KR100761486B1 (en) | Phage-Dependent Superproduction of Biologically Active Protein and Peptides | |
JPH0376580A (en) | Escherichia coli manifestation vector and production of antiviral protein using the same | |
RU2105812C1 (en) | Polypeptide eliciting urate oxidase activity, dna fragment determining expression of polypeptide eliciting urate oxidase activity (variants), expression vector containing dna fragment determining expression of polypeptide eliciting urate oxidase activity (variants), strain expressing polypeptide eliciting urate oxidase activity (variants), method of producing polypeptide eliciting urate oxidase activity | |
JPH01502638A (en) | Polypeptides with activity against Gram-positive and Gram-negative bacteria | |
JP2001017182A (en) | PRODUCTION OF POLY-gamma-GLUTAMIC ACID | |
FERREIRA et al. | Properties and crystallization of a genetically engineered, water‐soluble derivative of penicillin‐binding protein 5 of Escherichia coli K12 | |
EP0668911A1 (en) | Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor | |
JPH04502260A (en) | N-acetylmuramidase M1 | |
Engel et al. | Enzymatic preparation of 1, 6-anhydro-muropeptides by immobilized murein hydrolases from Escherichia coli fused to staphylococcal protein A | |
CA2329255C (en) | Method of producing thy a-strains of vibrio cholerae, such strains and their use | |
JP3364972B2 (en) | Transglutaminase gene from fish | |
HUT52154A (en) | Recombinant interleukin-2 hybrid proteins. | |
JPH0372888A (en) | Acid-fast bacteria secretion manifestation vector and transformant | |
Chakraborty et al. | Overexpression, purification and characterization of recombinant salmon calcitonin, a therapeutic protein, in streptomyces avermitilis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
122 | Ep: pct application non-entry in european phase |